1
|
Siegel BI, Gust J. How Cancer Harms the Developing Brain: Long-Term Outcomes in Pediatric Cancer Survivors. Pediatr Neurol 2024; 156:91-98. [PMID: 38735088 DOI: 10.1016/j.pediatrneurol.2024.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 02/22/2024] [Accepted: 03/31/2024] [Indexed: 05/14/2024]
Abstract
Survival rates for pediatric cancer are improving, resulting in a rising need to understand and address long-term sequelae. In this narrative review, we summarize the effects of cancer and its treatment on the developing brain, with a focus on neurocognitive function in leukemia and pediatric brain tumor survivors. We then discuss possible mechanisms of brain injury and management considerations.
Collapse
Affiliation(s)
- Benjamin I Siegel
- Brain Tumor Institute, Children's National Hospital, Washington, District of Columbia; Division of Pediatric Hematology and Oncology, Children's National Hospital, Washington, District of Columbia
| | - Juliane Gust
- Department of Neurology, University of Washinton, Seattle, Washington; Seattle Children's Research Institute, Center for Integrative Brain Research, Seattle, Washington.
| |
Collapse
|
2
|
Alias H, Mohd Ranai N, Lau SCD, de Sonneville LMJ. Neuropsychological task outcomes among survivors of childhood acute lymphoblastic leukemia in Malaysia. Sci Rep 2024; 14:7915. [PMID: 38575744 PMCID: PMC10995164 DOI: 10.1038/s41598-024-58128-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 03/26/2024] [Indexed: 04/06/2024] Open
Abstract
This study intended to explore the neuropsychological ramifications in childhood acute lymphoblastic leukemia (ALL) survivors in Malaysia and to examine treatment-related sequelae. A case-control study was conducted over a 2-year period. Seventy-one survivors of childhood ALL who had completed treatment for a minimum of 1 year and were in remission, and 71 healthy volunteers were enlisted. To assess alertness (processing speed) and essential executive functioning skills such as working memory capacity, inhibition, cognitive flexibility, and sustained attention, seven measures from the Amsterdam Neuropsychological Tasks (ANT) program were chosen. Main outcome measures were speed, stability and accuracy of responses. Mean age at diagnosis was 4.50 years (SD ± 2.40) while mean age at study entry was 12.18 years (SD ± 3.14). Survivors of childhood ALL underperformed on 6 out of 7 ANT tasks, indicating poorer sustained attention, working memory capacity, executive visuomotor control, and cognitive flexibility. Duration of treatment, age at diagnosis, gender, and cumulative doses of chemotherapy were not found to correlate with any of the neuropsychological outcome measures. Childhood ALL survivors in our center demonstrated significantly poorer neuropsychological status compared to healthy controls.
Collapse
Affiliation(s)
- Hamidah Alias
- Department of Pediatrics, Faculty of Medicine, The National University of Malaysia, 56000, Cheras, Kuala Lumpur, Malaysia.
| | - Norashikin Mohd Ranai
- Department of Pediatrics, Faculty of Medicine, Universiti Teknologi Mara (UiTM), 47000, Shah Alam, Selangor, Malaysia
| | - Sie Chong Doris Lau
- Department of Pediatrics, Faculty of Medicine, The National University of Malaysia, 56000, Cheras, Kuala Lumpur, Malaysia
| | - Leo M J de Sonneville
- Clinical Neurodevelopmental Sciences, Faculty of Social Sciences, Leiden University, Wassenaarseweg 52, 2333 AK, Leiden, The Netherlands
| |
Collapse
|
3
|
de Ville de Goyet M, Kicinski M, Suciu S, Vandecruys E, Uyttebroeck A, Ferster A, Freycon C, Plat G, Thomas C, Barbati M, Dresse MF, Paillard C, Pluchart C, Simon P, Chantrain C, Minckes O, van der Werff Ten Bosch J, Bertrand Y, Rohrlich P, Millot F, Paulus R, Benoit Y, Piette C. Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studies. Discov Oncol 2024; 15:20. [PMID: 38285235 PMCID: PMC10825101 DOI: 10.1007/s12672-024-00869-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 01/19/2024] [Indexed: 01/30/2024] Open
Abstract
Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and radiotherapy. This observational retrospective study evaluated the cumulative incidence of neurological late effects among 890 childhood ALL survivors treated in EORTC CLG trials (58741, 58831/2 and 58881) between 1971 and 1998. Median follow-up was 19 years and interquartile range of the follow-up was 15-22 years. At 20 years from the end of treatment, approximately 66% of patients from the 58741 trial (accrual time: 1971-1978) and approximately 15% from the more recent trials had cognitive disturbance grade 1 or higher. Cumulative incidences at 20 years from treatment end of seizures, stroke and leukoencephalopathy were respectively 45%, 16% and 62% in study 58741, 13%, 2% and 5% in study 58831/2, and 8%, 2% and 3% in study 58881. Patients who were 10-17 years of age at diagnosis had a higher incidence of stroke and leukoencephalopathy as compared to those less than 6 years of age. Noteworthy, all neurological late effects continued to occur beyond 5 years after end of treatment. This retrospective study highlights the frequency of neurological late effects in survivors of childhood ALL. With the increase of the overall survival of ALL patients, the role and potential benefit of longitudinal neurological screening should be evaluated in further studies as these neurological late effects become an important public health challenge. This study is part of the larger EORTC CLG 58 Late Adverse Effects (LAE) study (ClinicalTrials.gov Identifier NCT01298388, date of registration February 16, 2011).
Collapse
Affiliation(s)
- Maëlle de Ville de Goyet
- Department of Paediatric Haematology-Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | | | | | - Els Vandecruys
- Department of Paediatric Haematology-Oncology, Ghent University Hospital, Ghent, Belgium
| | - Anne Uyttebroeck
- Department of Paediatric Haematology-Oncology, University Hospital Leuven, Louvain, Belgium
| | - Alina Ferster
- Department of Haemato Oncology, HUDERF (ULB), Brussels, Belgium
| | - Claire Freycon
- Department of Paediatric Haematology-Oncology, CHU Grenoble, Grenoble, France
| | - Geneviève Plat
- Department of Haematology, CHU Toulouse, Toulouse, France
| | | | - Mélissa Barbati
- Department of Paediatric Haematology-Oncology, CHRU Lille, Lille, France
| | - Marie-Françoise Dresse
- Department of Paediatrics, University Hospital Liège and University of Liège, Liège, Belgium
| | - Catherine Paillard
- Department of Paediatric Haematology-Oncology, CHRU Strasbourg, Strasbourg, France
| | - Claire Pluchart
- Department of Paediatric Haematology and Oncology, CHU Reims, Reims, France
| | | | | | - Odile Minckes
- Department of Paediatric Haematology-Oncology, CHU Caen, Caen, France
| | | | - Yves Bertrand
- Department of Paediatric Onco-Haematology, Lyon University Hospital, Hospices Civils de Lyon and, Université Claude Bernard Lyon, Lyon, France
| | - Pierre Rohrlich
- Division of Paediatric Haematology-Oncology, CHU Nice, Nice, France
| | - Frederic Millot
- Department of Paediatric Haematology-Oncology, CHU Poitiers, Poitiers, France
| | | | - Yves Benoit
- Department of Paediatric Haematology-Oncology, Ghent University Hospital, Ghent, Belgium
| | - Caroline Piette
- Department of Paediatrics, University Hospital Liège and University of Liège, Liège, Belgium.
- Service de Pédiatrie, CHU Liège, Avenue de l'Hôpital 1, 4000 Liège, Belgium.
| |
Collapse
|
4
|
Hesko C, Liu W, Srivastava D, Brinkman TM, Diller L, Gibson TM, Oeffinger KC, Leisenring WM, Howell R, Armstrong GT, Krull KR, Henderson TO. Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer 2023; 129:2904-2914. [PMID: 37199722 PMCID: PMC10523930 DOI: 10.1002/cncr.34847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Revised: 04/12/2023] [Accepted: 04/13/2023] [Indexed: 05/19/2023]
Abstract
BACKGROUND Despite survival improvements, there is a paucity of data on neurocognitive outcomes in neuroblastoma survivors. This study addresses this literature gap. METHODS Neurocognitive impairments in survivors were compared to sibling controls from the Childhood Cancer Survivor Study (CCSS) using the CCSS Neurocognitive Questionnaire. Impaired emotional regulation, organization, task efficiency, and memory defined as scores ≥90th percentile of sibling norms. Modified Poisson regression models evaluated associations with treatment exposures, era of diagnosis, and chronic conditions. Analyses were stratified by age at diagnosis (≤1 and >1 year) as proxy for lower versus higher risk disease. RESULTS Survivors (N = 837; median [range] age, 25 [17-58] years, age diagnosed, 1 [0-21] years) were compared to sibling controls (N = 728; age, 32 [16-43] years). Survivors had higher risk of impaired task efficiency (≤1 year relative risk [RR], 1.48; 95% confidence interval [CI], 1.08-2.03; >1 year RR, 1.58; 95% CI, 1.22-2.06) and emotional regulation (≤1 year RR, 1.51; 95% CI, 1.07-2.12; >1 year RR, 1.44; 95% CI, 1.06-1.95). Impaired task efficiency associated with platinum exposure (≤1 year RR, 1.74; 95% CI, 1.01-2.97), hearing loss (≤1 year RR, 1.95; 95% CI, 1.26-3.00; >1 year RR, 1.56; 95% CI, 1.09-2.24), cardiovascular (≤1 year RR, 1.83; 95% CI, 1.15-2.89; >1 year RR, 1.74; 95% CI, 1.12-2.69), neurologic (≤1 year RR, 2.00; 95% CI, 1.32-3.03; >1 year RR, 2.29; 95% CI, 1.64-3.21), and respiratory (>1 year RR, 2.35; 95% CI, 1.60-3.45) conditions. Survivors ≤1 year; female sex (RR, 1.54; 95% CI, 1.02-2.33), cardiovascular (RR, 1.71; 95% CI, 1.08-2.70) and respiratory (RR, 1.99; 95% CI, 1.14-3.49) conditions associated impaired emotional regulation. Survivors were less likely to be employed full-time (p < .0001), graduate college (p = .035), and live independently (p < .0001). CONCLUSIONS Neuroblastoma survivors report neurocognitive impairment impacting adult milestones. Identified health conditions and treatment exposures can be targeted to improve outcomes. PLAIN LANGUAGE SUMMARY Survival rates continue to improve in patients with neuroblastoma. There is a lack of information regarding neurocognitive outcomes in neuroblastoma survivors; most studies examined survivors of leukemia or brain tumors. In this study, 837 adult survivors of childhood neuroblastoma were compared to siblings from the Childhood Cancer Survivorship Study. Survivors had a 50% higher risk of impairment with attention/processing speed (task efficiency) and emotional reactivity/frustration tolerance (emotional regulation). Survivors were less likely to reach adult milestones such as living independently. Survivors with chronic health conditions are at a higher risk of impairment. Early identification and aggressive management of chronic conditions may help mitigate the level of impairment.
Collapse
Affiliation(s)
- Caroline Hesko
- University of Vermont Children’s Hospital, Burlington, VT
| | - Wei Liu
- St. Jude Children’s Research Hospital, Memphis, TN
| | | | | | - Lisa Diller
- Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
| | | | | | | | - Rebecca Howell
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | |
Collapse
|
5
|
Schwartz LF, Dhaduk R, Howell CR, Brinkman TM, Ehrhardt MJ, Delaney A, Srivastava DK, Lanctot JQ, Armstrong GT, Robison LL, Hudson MM, Ness KK, Henderson TO. The Association of Neighborhood Characteristics and Frailty in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2023; 32:1021-1029. [PMID: 37040194 PMCID: PMC10524118 DOI: 10.1158/1055-9965.epi-22-1322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 03/03/2023] [Accepted: 04/07/2023] [Indexed: 04/12/2023] Open
Abstract
BACKGROUND Childhood cancer survivors experience reduced physiologic reserve, or frailty, earlier and more frequently than peers. In other populations, frailty is impacted by one's neighborhood. This study's purpose was to evaluate associations between neighborhood characteristics and frailty in childhood cancer survivors. METHODS Participants in the St. Jude Lifetime Cohort Study with geocoded residential addresses were analyzed. Pre-frailty/Frailty was defined as having 1-2/≥3 of sarcopenia, muscle weakness, poor endurance, slow walking speed, and exhaustion from direct assessments. Neighborhood characteristics [e.g., access to exercise opportunities and healthy food, neighborhood socioeconomic status (nSES), and rurality/urbanicity] were determined using publicly available geospatial data. Nested multivariable logistic regression models identified associations between neighborhood characteristics and pre-frailty/frailty, adjusting for chronic health conditions, individual health behaviors and socio-demographics, and high-risk cancer treatment exposures. RESULTS For our cohort (N = 3,806, 46.79% female, 81.40% white, mean age 33.63±9.91 years), compared with non-frail survivors (n = 2,573; 67.6%), pre-frail (n = 900; 23.6%) and frail survivors (n = 333; 8.7%) were more likely to live in neighborhoods with decreased exercise opportunities (frail OR: 1.62, 1.26-2.09), reduced healthy food access (pre-frail OR: 1.28, 1.08-1.51; frail OR: 1.36, 1.06-1.75), and lower nSES (pre-frail OR: 1.31, 1.12-1.52; frail OR: 1.64, 1.30-2.07). Participants had 8% increased odds (95% confidence interval, 2%-14%) of being pre-frail/frail if they lived in "resource poor" neighborhoods as opposed to "resource rich" neighborhoods after adjusting for other pre-frailty/frailty risk factors. CONCLUSIONS The neighborhood a childhood cancer survivor resides in as an adult is associated with pre-frailty/frailty. IMPACT This study provides valuable information for creating interventions using neighborhood-level factors to mitigate frailty and improve health outcomes in survivors. See related commentary by Bhandari and Armenian, p. 997.
Collapse
Affiliation(s)
- Lindsay F. Schwartz
- University of Chicago Comer Children’s Hospital, 5721 S. Maryland Avenue, Chicago, Illinois, 60637, United States
| | - Rikeenkumar Dhaduk
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Carrie R. Howell
- The University of Alabama at Birmingham, 1720 University Blvd, Birmingham, Alabama, 35294, United States
| | - Tara M. Brinkman
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Matthew J. Ehrhardt
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Angela Delaney
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Deo Kumar Srivastava
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Jennifer Q. Lanctot
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Gregory T. Armstrong
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Leslie L. Robison
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Melissa M. Hudson
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Kirsten K. Ness
- St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, 38105, United States
| | - Tara. O. Henderson
- University of Chicago Comer Children’s Hospital, 5721 S. Maryland Avenue, Chicago, Illinois, 60637, United States
| |
Collapse
|
6
|
Zhang Y, Zhang Y, Shen C, Hao S, Duan W, Liu L, Wei H. Ionizing radiation alters functional neurotransmission in Drosophila larvae. Front Cell Neurosci 2023; 17:1151489. [PMID: 37484822 PMCID: PMC10357008 DOI: 10.3389/fncel.2023.1151489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 06/22/2023] [Indexed: 07/25/2023] Open
Abstract
Introduction Patients undergoing cranial ionizing radiation therapy for brain malignancies are at increased risk of long-term neurocognitive decline, which is poorly understood and currently untreatable. Although the molecular pathogenesis has been intensively researched in many organisms, whether and how ionizing radiation alters functional neurotransmission remains unknown. This is the first study addressing physiological changes in neurotransmission after ionizing radiation exposure. Methods To elucidate the cellular mechanisms of radiation damage, using calcium imaging, we analyzed the effects of ionizing radiation on the neurotransmitter-evoked responses of prothoracicotropic hormone (PTTH)-releasing neurons in Drosophila larvae, which play essential roles in normal larval development. Results The neurotransmitters dopamine and tyramine decreased intracellular calcium levels of PTTH neurons in a dose-dependent manner. In gamma irradiated third-instar larvae, a dose of 25 Gy increased the sensitivity of PTTH neurons to dopamine and tyramine, and delayed development, possibly in response to abnormal functional neurotransmission. This irradiation level did not affect the viability and arborization of PTTH neurons and successful survival to adulthood. Exposure to a 40-Gy dose of gamma irradiation decreased the neurotransmitter sensitivity, physiological viability and axo-dendritic length of PTTH neurons. These serious damages led to substantial developmental delays and a precipitous reduction in the percentage of larvae that survived to adulthood. Our results demonstrate that gamma irradiation alters neurotransmitter-evoked responses, indicating synapses are vulnerable targets of ionizing radiation. Discussion The current study provides new insights into ionizing radiation-induced disruption of physiological neurotransmitter signaling, which should be considered in preventive therapeutic interventions to reduce risks of neurological deficits after photon therapy.
Collapse
Affiliation(s)
- Yi Zhang
- North China Research Institute of Electro-Optics, Beijing, China
| | - Yihao Zhang
- State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- College of Life Sciences, University of the Chinese Academy of Sciences, Beijing, China
| | - Cong Shen
- China Electronics Technology Group Corporation No. 45 Research Institute, Beijing, China
| | - Shun Hao
- State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- College of Life Sciences, University of the Chinese Academy of Sciences, Beijing, China
| | - Wenlan Duan
- State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- College of Life Sciences, University of the Chinese Academy of Sciences, Beijing, China
| | - Li Liu
- State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- College of Life Sciences, University of the Chinese Academy of Sciences, Beijing, China
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
| | - Hongying Wei
- State Key Laboratory of Brain and Cognitive Science, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- College of Life Sciences, University of the Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
7
|
Li B, Yabluchanskiy A, Tarantini S, Allu SR, Şencan-Eğilmez I, Leng J, Alfadhel MAH, Porter JE, Fu B, Ran C, Erdener SE, Boas DA, Vinogradov SA, Sonntag WE, Csiszar A, Ungvari Z, Sakadžić S. Measurements of cerebral microvascular blood flow, oxygenation, and morphology in a mouse model of whole-brain irradiation-induced cognitive impairment by two-photon microscopy and optical coherence tomography: evidence for microvascular injury in the cerebral white matter. GeroScience 2023; 45:1491-1510. [PMID: 36792820 PMCID: PMC10400746 DOI: 10.1007/s11357-023-00735-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 01/17/2023] [Indexed: 02/17/2023] Open
Abstract
Whole-brain irradiation (WBI, also known as whole-brain radiation therapy) is a mainstay treatment modality for patients with multiple brain metastases. It is also used as a prophylactic treatment for microscopic tumors that cannot be detected by magnetic resonance imaging. WBI induces a progressive cognitive decline in ~ 50% of the patients surviving over 6 months, significantly compromising the quality of life. There is increasing preclinical evidence that radiation-induced injury to the cerebral microvasculature and accelerated neurovascular senescence plays a central role in this side effect of WBI. To better understand this side effect, male C57BL/6 mice were first subjected to a clinically relevant protocol of fractionated WBI (5 Gy, two doses per week, for 4 weeks). Nine months post the WBI treatment, we applied two-photon microscopy and Doppler optical coherence tomography to measure capillary red-blood-cell (RBC) flux, capillary morphology, and microvascular oxygen partial pressure (PO2) in the cerebral somatosensory cortex in the awake, head-restrained, WPI-treated mice and their age-matched controls, through a cover-glass-sealed chronic cranial window. Thanks to the extended penetration depth with the fluorophore - Alexa680, measurements of capillary blood flow properties (e.g., RBC flux, speed, and linear density) in the cerebral subcortical white matter were enabled. We found that the WBI-treated mice exhibited a significantly decreased capillary RBC flux in the white matter. WBI also caused a significant reduction in capillary diameter, as well as a large (although insignificant) reduction in segment density at the deeper cortical layers (e.g., 600-700 μm), while the other morphological properties (e.g., segment length and tortuosity) were not obviously affected. In addition, we found that PO2 measured in the arterioles and venules, as well as the calculated oxygen saturation and oxygen extraction fraction, were not obviously affected by WBI. Lastly, WBI was associated with a significant increase in the erythrocyte-associated transients of PO2, while the changes of other cerebral capillary PO2 properties (e.g., capillary mean-PO2, RBC-PO2, and InterRBC-PO2) were not significant. Collectively, our findings support the notion that WBI results in persistent cerebral white matter microvascular impairment, which likely contributes to the WBI-induced brain injury and cognitive decline. Further studies are warranted to assess the WBI-induced changes in brain tissue oxygenation and malfunction of the white matter microvasculature as well.
Collapse
Affiliation(s)
- Baoqiang Li
- Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Andriy Yabluchanskiy
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- The Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
| | - Stefano Tarantini
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- The Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Public Health, Semmelweis University, Budapest, 1083, Hungary
| | - Srinivasa Rao Allu
- Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Ikbal Şencan-Eğilmez
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
- Biophotonics Research Center, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Ji Leng
- Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China
| | - Mohammed Ali H Alfadhel
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Jason E Porter
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Buyin Fu
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Chongzhao Ran
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
| | - Sefik Evren Erdener
- Department of Biomedical Engineering, Boston University, Boston, MA, 02215, USA
| | - David A Boas
- Department of Biomedical Engineering, Boston University, Boston, MA, 02215, USA
| | - Sergei A Vinogradov
- Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - William E Sonntag
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- The Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
| | - Anna Csiszar
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- The Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Translational Medicine, Semmelweis University, Budapest, 1083, Hungary
| | - Zoltan Ungvari
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
- Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
- The Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
- International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Public Health, Semmelweis University, Budapest, 1083, Hungary.
| | - Sava Sakadžić
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.
| |
Collapse
|
8
|
Perez WD, Perez-Torres CJ. Neurocognitive and radiological changes after cranial radiation therapy in humans and rodents: a systematic review. Int J Radiat Biol 2023; 99:119-137. [PMID: 35511499 DOI: 10.1080/09553002.2022.2074167] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Radiation-induced brain injury is a common long-term side effect for brain cancer survivors, leading to a reduced quality of life. Although there is growing research pertaining to this topic, the relationship between cognitive and radiologically detected lesions of radiation-induced brain injury in humans remains unclear. Furthermore, clinically translatable similarities between rodent models and human findings are also undefined. The objective of this review is to then identify the current evidence of radiation-induced brain injury in humans and to compare these findings to current rodent models of radiation-induced brain injury. METHODS This review includes an examination of the current literature on cognitive and radiological characteristics of radiation-induced brain injury in humans and rodents. A thorough search was conducted on PubMed, Web of Science, and Scopus to identify studies that performed cognitive assessments and magnetic resonance imaging techniques on either humans or rodents after cranial radiation therapy. A qualitative synthesis of the data is herein reported. RESULTS A total of 153 studies pertaining to cognitively or radiologically detected radiation injury of the brain are included in this systematic review; 106 studies provided data on humans while 47 studies provided data on rodents. Cognitive deficits in humans manifest across multiple domains after brain irradiation. Radiological evidence in humans highlight various neuroimaging-detectable changes post-irradiation. It is unclear, however, whether these findings reflect ground truth or research interests. Additionally, rodent models do not comprehensively reproduce characteristics of cognitive and radiological injury currently identified in humans. CONCLUSION This systematic review demonstrates that associations between and within cognitive and radiological radiation-induced brain injuries often rely on the type of assessment. Well-designed studies that evaluate the spectrum of potential injury are required for a precise understanding of not only the clinical significance of radiation-induced brain injury in humans, but also how to replicate injury development in pre-clinical models.
Collapse
Affiliation(s)
- Whitney D Perez
- School of Health Sciences, Purdue University, West Lafayette, IN, USA
| | - Carlos J Perez-Torres
- School of Health Sciences, Purdue University, West Lafayette, IN, USA.,Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, USA.,Academy of Integrated Science, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.,School of Neuroscience, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA
| |
Collapse
|
9
|
Cole PD, Kim SY, Li Y, Schembri A, Kelly KM, Sulis ML, Vrooman L, Welch JJG, Ramjan S, Silverman LB, Sands SA. Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Support Care Cancer 2023; 31:109. [PMID: 36625831 DOI: 10.1007/s00520-022-07566-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 12/27/2022] [Indexed: 01/11/2023]
Abstract
PURPOSE Neurocognitive impairment is frequently observed among survivors of childhood acute lymphoblastic leukemia (ALL) within the domains of attention, working memory, processing speed, executive functioning, and learning and memory. However, few studies have characterized the trajectory of treatment-induced changes in neurocognitive function beginning in the first months of treatment, to test whether early changes predict impairment among survivors. If correct, we hypothesize that those children who are most susceptible to early impairment would be ideal subjects for clinical trials testing interventions designed to protect against treatment-related neurocognitive decline. METHODS In this pilot study, we prospectively assessed neurocognitive functioning (attention, working memory, executive function, visual learning, and processing speed), using the Cogstate computerized battery at six time points during the 2 years of chemotherapy treatment and 1-year post-treatment (Dana-Farber Cancer Institute ALL Consortium protocol 11-001; NCT01574274). RESULTS Forty-three patients with ALL consented to serial neurocognitive testing. Of the 31 participants who remained on study through the final time point, 1 year after completion of chemotherapy, 28 (90%) completed at least five of six planned Cogstate testing time points. Performance and completion checks indicated a high tolerability (≥ 88%) for all subtests. One year after completion of treatment, 10 of 29 patients (34%) exhibited neurocognitive function more than 2 standard deviations below age-matched norms on one or more Cogstate subtests. CONCLUSIONS Serial collection of neurocognitive data (within a month of diagnosis with ALL, during therapy, and 1-year post-treatment) is feasible and can be informative for evaluating treatment-related neurocognitive impairment.
Collapse
Affiliation(s)
- Peter D Cole
- Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - Soo Young Kim
- Department of Psychiatry & Behavioral Sciences and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY, 10022, USA
| | - Yuelin Li
- Department of Psychiatry & Behavioral Sciences and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY, 10022, USA
| | | | - Kara M Kelly
- Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Maria-Luisa Sulis
- Department of Psychiatry & Behavioral Sciences and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY, 10022, USA
| | - Lynda Vrooman
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Jennifer J G Welch
- Hasbro Children's Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - Sameera Ramjan
- Department of Psychiatry & Behavioral Sciences and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY, 10022, USA
| | - Lewis B Silverman
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Stephen A Sands
- Department of Psychiatry & Behavioral Sciences and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY, 10022, USA.
| |
Collapse
|
10
|
Clinical outcomes of patients with multiple courses of radiosurgery for brain metastases from non-small cell lung cancer. Sci Rep 2022; 12:10712. [PMID: 35739135 PMCID: PMC9226031 DOI: 10.1038/s41598-022-13853-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 05/30/2022] [Indexed: 11/18/2022] Open
Abstract
We investigated the long-term clinical outcomes of patients who underwent multiple courses (≥ 5) of gamma knife radiosurgery (GKRS) due to recurrent brain metastases (BM) from non-small cell lung cancer (NSCLC). Between December 2001 and July 2019, consecutive 2571 patients underwent GKRS for BM from NSCLC. Clinical and radiological outcomes were investigated in 76 patients who underwent GKRS ≥ 5 times. The median follow-up period after the diagnosis of NSCLC was 54.6 months (range 14.5–159.1 months). The median number of GKRS procedures per patient was six (range 5–15). Actuarial post-GKRS survival rates at 1, 2, 3, 4, and 5 years following initial GKRS were 88.1%, 79.5%, 65.3%, 51.4%, and 37.3%, respectively. No significant difference in overall survival was observed between patients (n = 22) with whole-brain radiotherapy (WBRT) and patients (n = 54) without WBRT (p = 0.076). The incidence of radiation-induced leukoencephalopathy was 64% and 18% in patients with and without WBRT, respectively (p < 0.0001). Multiple courses of SRS are a tolerable and effective treatment option for recurrent BM from NSCLC. Repeat SRS may be an alternative treatment option to avoid or delay WBRT.
Collapse
|
11
|
Voon NS, Manan HA, Yahya N. Diffusion tensor imaging indices as biomarkers for cognitive changes following paediatric radiotherapy: a systematic review and meta-analysis. Strahlenther Onkol 2022; 198:409-426. [PMID: 35238981 DOI: 10.1007/s00066-022-01905-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Accepted: 01/23/2022] [Indexed: 11/30/2022]
Abstract
Diffusion tensor imaging (DTI) can detect subtle manifestations of white matter (WM) injury following paediatric radiotherapy, which may be a potential biomarker for cognitive changes. This study aimed to synthesise the relationships between DTI indices and cognitive changes following paediatric radiotherapy through systematic review and meta-analysis. PubMed and Scopus electronic databases were used to identify eligible studies. Quality assessment was performed using the National Institute of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Information on demographics, DTI changes, and associations to cognitive outcomes were extracted. Meta-analyses were performed on DTI changes in specific anatomical locations. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in the preparation of this report. Eighteen studies were included (median study size: 21; range 18-146). 17/18 studies showed significant cognitive decline following irradiation. Meta-analyses found significant cognitive changes within patient's group of acute lymphoblastic leukaemia (ALL; standard mean differences [SMD] = -0.075, P = 0.01) and brain tumours (BT; SMD = -1.037, P ≤ 0.001) compared to control/baseline. Both groups also had significantly lower fractional anisotropy (FA) scores in the corpus callosum (ALL: SMD = -0.979, P = 0.002; BT: SMD = -1.025, P < 0.001). Decreased FA was consistently associated with cognitive decline. Correlation on WMFA integrity to cognitive domains was statistically significant (Z = 9.86, P < 0.001) with a large effect size (r = 0.52). White matter tract integrity of the corpus callosum measured with FA has the potential to be a biomarker for radiotherapy-related cognitive decline. Inclusion of DTI in follow-up imaging should be encouraged.
Collapse
Affiliation(s)
- Noor Shatirah Voon
- Diagnostic Imaging and Radiotherapy, Faculty of Health Sciences, National University of Malaysia, Jalan Raja Muda Aziz, 50300, Kuala Lumpur, Malaysia
| | - Hanani Abdul Manan
- Functional Image Processing Laboratory, Department of Radiology, University Kebangsaan Malaysia Medical Centre, Cheras, 56000, Kuala Lumpur, Malaysia
| | - Noorazrul Yahya
- Diagnostic Imaging and Radiotherapy, Faculty of Health Sciences, National University of Malaysia, Jalan Raja Muda Aziz, 50300, Kuala Lumpur, Malaysia.
| |
Collapse
|
12
|
Svärd D, Erfurth EM, Hellerstedt R, Mannfolk P, Mårtensson J, Sundgren P, Follin C. Cognitive interference processing in adult survivors of childhood acute lymphoblastic leukemia using functional magnetic resonance imaging. Acta Oncol 2022; 61:333-340. [PMID: 34637675 DOI: 10.1080/0284186x.2021.1987514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Childhood acute lymphoblastic leukemia (ALL) is associated with cognitive impairment in adulthood. Cognitive interference processing and its correlated functional magnetic resonance imaging (fMRI) activity in the brain have not yet been studied in this patient group. MATERIAL Twenty-six adult childhood ALL survivors (median [interquartile range {IQR}] age, 40.0 [37.0-42.3] years) were investigated at median age (IQR), 35.0 (32.0-37.0) years after treatment with intrathecal and intravenous chemotherapy as well as cranial radiotherapy (24 Gy) and compared with 26 matched controls (median [IQR] age, 37.5 [33.0-41.5] years). METHODS Cognitive interference processing was investigated in terms of behavioral performance (response times [ms] and accuracy performance [%]) and fMRI activity in the cingulo-fronto-parietal (CFP) attention network as well as other parts of the brain using the multisource interference task (MSIT). RESULTS ALL survivors had longer response times and reduced accuracy performance during cognitive interference processing (median [IQR] interference effect, 371.9 [314.7-453.3] ms and 6.7 [4.2-14.7]%, respectively) comparedwith controls (303.7 [275.0-376.7] ms and 2.3 [1.6-4.3]%, respectively), but did not exhibit altered fMRI activity in the CFP attention network or elsewhere in the brain. CONCLUSION Adult childhood ALL survivors demonstrated impaired behavioral performance but no altered fMRI activity when performing cognitive interference processing when compared with controls. The results can be used to better characterize this patient group and to optimize follow-up care and support for these individuals.
Collapse
Affiliation(s)
- Daniel Svärd
- Department of Diagnostic Radiology, Lund University, Lund, Sweden
- Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden
| | - Eva Marie Erfurth
- Department of Endocrinology, Skåne University Hospital, Lund, Sweden
| | - Robin Hellerstedt
- Department of Psychology, University of Cambridge, Cambridge, United Kingdom
| | - Peter Mannfolk
- Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden
| | - Johan Mårtensson
- Department of Logopedics, Phoniatrics and Audiology, Lund University, Lund, Sweden
| | - Pia Sundgren
- Department of Diagnostic Radiology, Lund University, Lund, Sweden
- Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden
- Lund University BioImaging Center, Lund University, Lund, Sweden
| | - Cecilia Follin
- Department of Oncology, Skåne University Hospital, Lund, Sweden
| |
Collapse
|
13
|
Ravera S, Vigliarolo T, Bruno S, Morandi F, Marimpietri D, Sabatini F, Dagnino M, Petretto A, Bartolucci M, Muraca M, Biasin E, Haupt R, Zecca M, Fagioli F, Cilloni D, Podestà M, Frassoni F. Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. Cancers (Basel) 2021; 13:cancers13205214. [PMID: 34680366 PMCID: PMC8534026 DOI: 10.3390/cancers13205214] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 10/12/2021] [Accepted: 10/14/2021] [Indexed: 12/30/2022] Open
Abstract
Simple Summary Childhood cancer survivors (CCS) display a higher risk of developing second malignant tumors and chronic diseases compared with aged-matched controls because of chemo/radiotherapy. This early frailty seems associated with accelerated cell aging, a process correlated with altered mitochondrial energy production. Therefore, this work aims to shed light on the mechanisms involved in chemo/radiotherapy-induced early aging, morbidities, and the risk of developing second tumors in CCS through a biochemical and molecular approach. The identification of crucial mechanisms involved in the CCS chemo/radiotherapy-related pathological conditions will allow identifying therapeutic targets to develop appropriate risk-based care and interventions, minimize morbidities, and maximize the quality of life in the cancer survivor population. Abstract Survival rates of childhood cancer patients have improved over the past four decades, although cancer treatments increase the risk of developing chronic diseases typical of aging. Thus, we aimed to identify molecular/metabolic cellular alterations responsible for early aging in childhood cancer survivors (CCS). Biochemical, proteomic, and molecular biology analyses were conducted on mononuclear cells (MNCs) isolated from peripheral blood of 196 CCS, the results being compared with those obtained on MNCs of 154 healthy subjects. CCS-MNCs showed inefficient oxidative phosphorylation associated with low energy status, and increased lipid peroxidation and lactate fermentation compared with age-matched normal controls. According to a mathematical model based on biochemical parameters, CCS-MNCs showed significantly higher metabolic ages than their real ages. The dysfunctional metabolism of CCS-MNCs is associated with lower expression levels of genes and proteins involved in mitochondrial biogenesis and metabolism regulation, such as CLUH, PGC1-alpha, and SIRT6 in CCS, not observed in the age-matched healthy or elderly subjects. In conclusion, our study identified some biochemical and molecular alterations possibly contributing to the pathophysiology of aging and metabolic deficiencies in CCS. These results identify new targets for pharmacological interventions to restore mitochondrial function, slowing down the aging-associated pathologies in CCS.
Collapse
Affiliation(s)
- Silvia Ravera
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
- Department of Experimental Medicine, University of Genoa, 16132 Genoa, Italy;
- Correspondence: ; Tel.: +39-010-335-7871
| | - Tiziana Vigliarolo
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
| | - Silvia Bruno
- Department of Experimental Medicine, University of Genoa, 16132 Genoa, Italy;
| | - Fabio Morandi
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
| | - Danilo Marimpietri
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
| | - Federica Sabatini
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
| | - Monica Dagnino
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
| | - Andrea Petretto
- Core Facilities-Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (A.P.); (M.B.)
| | - Martina Bartolucci
- Core Facilities-Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (A.P.); (M.B.)
| | - Monica Muraca
- Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (M.M.); (R.H.)
| | - Eleonora Biasin
- Department of Pediatric Onco-Haematology, Regina Margherita Children’s Hospital, University of Turin, 10126 Turin, Italy; (E.B.); (F.F.)
| | - Riccardo Haupt
- Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (M.M.); (R.H.)
| | - Marco Zecca
- Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy;
| | - Franca Fagioli
- Department of Pediatric Onco-Haematology, Regina Margherita Children’s Hospital, University of Turin, 10126 Turin, Italy; (E.B.); (F.F.)
| | - Daniela Cilloni
- Department of Clinical and Biological Sciences, School of Medicine, University of Turin, 10124 Turin, Italy;
| | - Marina Podestà
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
| | - Francesco Frassoni
- Stem Cell Laboratory and Cell Therapy Center, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; (T.V.); (F.M.); (D.M.); (F.S.); (M.D.); (M.P.); (F.F.)
- Department of Clinical and Biological Sciences, School of Medicine, University of Turin, 10124 Turin, Italy;
- Department of Mathematics (DIMA), University of Genoa, 16146 Genoa, Italy
| |
Collapse
|
14
|
Harrison RA, Sharafeldin N, Rexer JL, Streck B, Petersen M, Henneghan AM, Kesler SR. Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms. Oncologist 2021; 26:e2021-e2033. [PMID: 34156729 DOI: 10.1002/onco.13867] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2020] [Accepted: 06/14/2021] [Indexed: 12/16/2022] Open
Abstract
Hematopoietic stem cell transplant (HSCT) plays a central role in the treatment of hematologic cancers. With the increasing survival of patients after HSCT, survivorship issues experienced by this population have become an important outcome. Cognitive impairment is an established sequela of HSCT, with studies to date establishing its presence, associated risk factors, and clinical phenotype. There are multiple potential contributors to cognitive impairment after HSCT. Efforts are ongoing to further characterize its clinical phenotype, associated biomarkers, and biologic underpinnings. A fundamental knowledge of post-HSCT cognitive impairment is of value for all clinicians who interface with this population, and further academic efforts are needed to more fully understand the impact of this cancer treatment on brain health. IMPLICATIONS FOR PRACTICE: As survival outcomes after hematopoietic stem cell transplant (HSCT) improve, an awareness of the post-treatment challenges faced by this population has become central to its care. HSCT can have a sustained and broad impact on brain health, causing cognitive dysfunction, fatigue, disturbed mood, and sleep. In affected patients, autonomy, return to work, relationships, and quality of life may all be affected. A fundamental fluency in this area is important for clinicians interfacing with HSCT survivors, facilitating the identification and management of cognitive dysfunction and concurrent symptom clusters, and stimulating interest in these sequelae as areas for future clinical research.
Collapse
Affiliation(s)
- Rebecca A Harrison
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Noha Sharafeldin
- Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Jennie L Rexer
- Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Brennan Streck
- Milken Institute School of Public Health, The George Washington University, Washington, DC, USA
| | - Melissa Petersen
- Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA
| | - Ashley M Henneghan
- School of Nursing, Dell School of Medicine, University of Texas at Austin, Austin, Texas, USA.,Department of Oncology, Dell School of Medicine, University of Texas at Austin, Austin, Texas, USA
| | - Shelli R Kesler
- School of Nursing, Dell School of Medicine, University of Texas at Austin, Austin, Texas, USA.,Department of Diagnostic Medicine, Dell School of Medicine, University of Texas at Austin, Austin, Texas, USA
| |
Collapse
|
15
|
Fox ME, Turner JA, Crosson B, Morris RD, King TZ. Functional Connectivity Networks and Their Recruitment During Working Memory Tasks in Adult Survivors of Childhood Brain Tumors. Brain Connect 2021; 11:822-837. [PMID: 33858201 DOI: 10.1089/brain.2020.0800] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Background: Assessments of functional connectivity of default mode network (DMN) and positive task-related networks (TRNs) using independent component analysis (ICA) may help describe long-term effects of childhood brain tumors and adjuvant treatments. Methods: Aiming to identify potential neuronal markers that may aid in prognosis and inform interventions to optimize outcomes, this study used ICA to evaluate the presence of functional connectivity networks and their recruitment during a letter n-back task in 23 adult survivors of childhood posterior fossa tumors (9 low grade, 14 high grade) at least 5 years past diagnosis compared with 40 age- and sex-matched healthy peers. Results: DMN components generally demonstrated increasing disengagement as task difficulty increased, and relationships between effective DMN disengagement and improved performance were observed in healthy controls (HCs). Low-grade brain tumor survivors (LGS) demonstrated unique patterns in DMN recruitment that suggested increased involvement of the medial prefrontal cortex in LGS during tasks. TRN components generally demonstrated increasing engagement, which was related to improved task performance in HCs for one executive control network (ECN) component. High-grade brain tumor survivors (HGS) demonstrated distinct challenges recruiting an ECN component at more difficult task levels and showed a relationship between recruitment of another ECN component and task performance, indicating a potential compensatory mechanism for some HGS. Conclusions: Findings suggest the importance of cognitive intervention in both survivor groups and the necessity to track LGS despite their cognitive abilities often resembling those of their healthy peers. Impact statement Distinct functional connectivity patterns were identified between both adult survivor of childhood brain tumor groups and peers during attention and working memory tasks, reflecting different damage and recovery from treatment. Survivors of low-grade tumors demonstrated unique patterns of recruitment of default mode network components in the context of similar cognitive abilities, whereas survivors of high-grade tumors demonstrated poorer cognitive abilities and may be utilizing compensatory executive control network components in the face of challenging tasks. Long-term clinical follow-up and cognitive remediation is warranted for both groups, including low grade cerebellar tumor patients who have traditionally not been monitored as closely.
Collapse
Affiliation(s)
- Michelle E Fox
- Department of Psychology, Georgia State University, Atlanta, Georgia, USA
| | - Jessica A Turner
- Department of Psychology, Georgia State University, Atlanta, Georgia, USA.,Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA
| | - Bruce Crosson
- Department of Psychology, Georgia State University, Atlanta, Georgia, USA.,Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA.,Departments of Neurology and of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.,Atlanta VA Center of Excellence for Visual and Neurocognitive Rehabilitation, Decatur, Georgia, USA
| | - Robin D Morris
- Department of Psychology, Georgia State University, Atlanta, Georgia, USA.,Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA
| | - Tricia Z King
- Department of Psychology, Georgia State University, Atlanta, Georgia, USA.,Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA
| |
Collapse
|
16
|
Triebel K, Anderson J, Nakkina SR, Vance DE. Can Breast Cancer Survivors Benefit from Speed of Processing Training? A Perspective Article on Treatment and Research. NURSING: RESEARCH AND REVIEWS 2021. [DOI: 10.2147/nrr.s312214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
17
|
Schuitema I, Alexander T, Hudson MM, Krull KR, Edelstein K. Aging in Adult Survivors of Childhood Cancer: Implications for Future Care. J Clin Oncol 2021; 39:1741-1751. [PMID: 33886351 DOI: 10.1200/jco.20.02534] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Affiliation(s)
- Ilse Schuitema
- Department of Health, Medical and Neuropsychology, Leiden University, Leiden, the Netherlands
| | - Tyler Alexander
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN
| | - Melissa M Hudson
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.,Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
| | - Kevin R Krull
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.,Department of Psychology, St Jude Children's Research Hospital, Memphis, TN
| | - Kim Edelstein
- Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| |
Collapse
|
18
|
Kesler SR, Sleurs C, McDonald BC, Deprez S, van der Plas E, Nieman BJ. Brain Imaging in Pediatric Cancer Survivors: Correlates of Cognitive Impairment. J Clin Oncol 2021; 39:1775-1785. [PMID: 33886371 DOI: 10.1200/jco.20.02315] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- Shelli R Kesler
- School of Nursing, Department of Diagnostic Medicine, Dell School of Medicine, Livestrong Cancer Institutes, Austin, TX
| | - Charlotte Sleurs
- Department of Oncology, Catholic University of Leuven, Leuven, Belgium.,Leuven Cancer Institute, Leuven, Belgium
| | - Brenna C McDonald
- Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Center for Neuroimaging, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - Sabine Deprez
- Leuven Cancer Institute, Leuven, Belgium.,Department of Imaging and Pathology, Catholic University of Leuven, Leuven, Belgium
| | - Ellen van der Plas
- Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, Iowa
| | - Brian J Nieman
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.,Ontario Institute for Cancer Research, Toronto, ON, Canada.,Translational Medicine, Hospital for Sick Children, Toronto, ON, Canada
| |
Collapse
|
19
|
van den Boogaard WMC, van den Heuvel-Eibrink MM, Hoeijmakers JHJ, Vermeij WP. Nutritional Preconditioning in Cancer Treatment in Relation to DNA Damage and Aging. ANNUAL REVIEW OF CANCER BIOLOGY 2021; 5:161-179. [PMID: 35474917 PMCID: PMC9037985 DOI: 10.1146/annurev-cancerbio-060820-090737] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Dietary restriction (DR) is the most successful nutritional intervention for extending lifespan and preserving health in numerous species. Reducing food intake triggers a protective response that shifts energy resources from growth to maintenance and resilience mechanisms. This so-called survival response has been shown to particularly increase life- and health span and decrease DNA damage in DNA repair-deficient mice exhibiting accelerated aging. Accumulation of DNA damage is the main cause of aging, but also of cancer. Moreover, radiotherapies and most chemotherapies are based on damaging DNA, consistent with their ability to induce toxicity and accelerate aging. Since fasting and DR decrease DNA damage and its effects, nutritional preconditioning holds promise for improving (cancer) therapy and preventing short- and long-term side effects of anticancer treatments. This review provides an overview of the link between aging and cancer, highlights important preclinical studies applying such nutritional preconditioning, and summarizes the first clinical trials implementing nutritional preconditioning in cancer treatment.
Collapse
Affiliation(s)
- Winnie M C van den Boogaard
- Genome Instability and Nutrition Research Group, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- Oncode Institute, 3521 AL Utrecht, The Netherlands
| | - Marry M van den Heuvel-Eibrink
- Pediatric Oncology Translational Research Group, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Jan H J Hoeijmakers
- Genome Instability and Nutrition Research Group, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- Oncode Institute, 3521 AL Utrecht, The Netherlands
- Department of Molecular Genetics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
- CECAD Forschungszentrum, University of Cologne, 50931 Cologne, Germany
| | - Wilbert P Vermeij
- Genome Instability and Nutrition Research Group, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- Oncode Institute, 3521 AL Utrecht, The Netherlands
| |
Collapse
|
20
|
When Childhood Cancer Becomes a Family Affair, It Really Hits Home. Pediatr Clin North Am 2020; 67:1021-1031. [PMID: 33131532 DOI: 10.1016/j.pcl.2020.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In this article, a father and son describe the experience of childhood leukemia treatment and its aftermath with the unique perspective of a parent who is also a pediatric oncologist. An illness that began with an apparently favorable prognosis was transformed by an early relapse, followed by unexpected complications and difficult treatment decisions. Despite unfavorable statistics, the son is a long-term survivor with an overall excellent quality of life, despite several late events and effects. His father, in the meantime, gained insights that now inform his own practice.
Collapse
|
21
|
Age differences in foraging and executive functions: A cross-sectional study. J Exp Child Psychol 2020; 198:104910. [DOI: 10.1016/j.jecp.2020.104910] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Revised: 05/18/2020] [Accepted: 05/18/2020] [Indexed: 11/23/2022]
|
22
|
Sakaguchi Y, Natsume J, Kidokoro H, Tanaka M, Okai Y, Ito Y, Yamamoto H, Ohno A, Nakata T, Nakane T, Kawai H, Taoka T, Muramatsu H, Naganawa S, Takahashi Y. Change of White Matter Integrity in Children With Hematopoietic Stem Cell Transplantation. Pediatr Neurol 2020; 111:78-84. [PMID: 32951667 DOI: 10.1016/j.pediatrneurol.2020.06.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 06/11/2020] [Accepted: 06/13/2020] [Indexed: 11/29/2022]
Abstract
BACKGROUND Advances in hematopoietic stem cell transplantation have improved the survival rate of malignant diseases and congenital immunodeficiencies. It has become important to assess long-term complications in survivors. To assess neurological abnormalities in children treated by transplantation, diffusion tensor imaging was performed. METHODS Forty children who underwent head diffusion tensor imaging before and after their first transplantation were enrolled. Patients with brain lesions on conventional MRI were excluded. Fractional anisotropy and mean diffusivity were compared between patients and 28 control subjects using tract-based spatial statistics. The Strengths and Difficulties Questionnaire was administered as a behavioral evaluation after transplantation, and diffusion tensor images of patients with and without behavioral abnormalities were compared. RESULTS The age of patients and controls was 0 to 19 years and 0 to 16 years, respectively. The date of diffusion tensor imaging was 10 to 57 days before and 40 to 153 days after transplantation. Tract-based spatial statistics showed fractional anisotropy reduction in widespread white matter in patients before and after transplantation. Mean diffusivity was high before transplantation and normalized after transplantation. Analysis comparing before and after hematopoietic stem cell transplantation shows no difference in fractional anisotropy and a higher mean diffusivity before hematopoietic stem cell transplantation. In patients with behavioral abnormalities, low fractional anisotropy and high mean diffusivity remained after transplantation. CONCLUSIONS Longitudinal diffusion tensor imaging showed white matter abnormalities in children without conventional MRI abnormalities, which were related to behavioral problems after transplantation. Diffusion tensor imaging is useful for behavioral assessment in children undergoing transplantation.
Collapse
Affiliation(s)
- Yoko Sakaguchi
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Jun Natsume
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; Brain and Mind Research Center, Nagoya University, Nagoya, Japan; Department of Developmental Disability Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| | - Hiroyuki Kidokoro
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; Brain and Mind Research Center, Nagoya University, Nagoya, Japan
| | - Masaharu Tanaka
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yu Okai
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yuji Ito
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; Brain and Mind Research Center, Nagoya University, Nagoya, Japan
| | - Hiroyuki Yamamoto
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; Brain and Mind Research Center, Nagoya University, Nagoya, Japan
| | - Atsuko Ohno
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Tomohiko Nakata
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Toshiki Nakane
- Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Hisashi Kawai
- Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Toshiaki Taoka
- Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Hideki Muramatsu
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Shinji Naganawa
- Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yoshiyuki Takahashi
- Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
23
|
Schroyen G, Meylaers M, Deprez S, Blommaert J, Smeets A, Jacobs S, Sunaert S, Sleurs C, Uyttebroeck A. Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients. J Chemother 2020; 32:327-343. [PMID: 32799637 DOI: 10.1080/1120009x.2020.1805239] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Due to the rising use of chemotherapy treatment in cancer patients and growing survival rates, therapy-induced neurotoxic side effects are increasingly reported. Given the ambiguity about the prevalence and severity of leukoencephalopathy, one of such toxic side effects, in non-central nervous system (CNS) cancer patients, we performed a systematic literature search using the PubMed/Medline database to summarize existing literature regarding leukoencephalopathy epidemiology in non-CNS cancer patients and its potential cognitive sequelae. The search was based on the following terms: ('MRI' OR 'T2-weighted MRI' OR 'FLAIR') AND ('cancer' OR 'tumour' OR 'leukaemia' OR 'neoplasms') AND ('chemotherapy' OR 'radiotherapy') AND ('posterior reversible encephalopathy' OR 'leukoencephalopathy' OR 'cerebral ischaemia' OR 'stroke'). Thirty-two studies discussing the occurrence of leukoencephalopathy in cancer patients were included, of which the majority investigated Acute Lymphoblastic Leukaemia (ALL) patients (n = 22).Regularly scanned ALL patients showed a prevalence of leukoencephalopathy between 17 - 87%, and 15 - 83% of patients presented with leukoencephalopathy when only scanned after a CNS event. When diagnosed with posterior reversible encephalopathy syndrome, 100% of patients showed leukoencephalopathy because its diagnosis is based in part on observable lesions. An increased prevalence was observed in ALL patients treated with higher doses of methotrexate (5 g/m2 MTX, 42 - 87%) when compared to lower doses (< 5 g/m2, 32 - 67%). By contrast, in breast cancer patients, white matter lesions were mainly detected in case of neurological symptoms, but not (yet) clearly associated with chemotherapy administration. However, chemotherapy treatment was associated with more infratentorial microbleeds in breast cancer patients . Up to 50% of other (neurologically asymptomatic) solid tumour patients presented white matter lesions, even years after treatment. When cognitive data were investigated, lesioned patients showed lower scores on neurocognitive tests in 50% of studies, years after ending therapy.In conclusion, leukoencephalopathy is well-documented for ALL patients (with a focus on methotrexate), but there is a lack of knowledge for other intravenous chemotherapeutics, other oncological populations, wider age ranges and possible risk factors (e.g. history of CNS event). Furthermore, the long-term neuropsychological impact and potential risk for neurodegenerative processes due to leukoencephalopathy remains inconclusive. Hence, large international databanks, epidemiological and prospective case-control studies are necessary to stratify risk groups for CNS-related side effects.
Collapse
Affiliation(s)
- Gwen Schroyen
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | | | - Sabine Deprez
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | | | - Ann Smeets
- Department of Oncology, KU Leuven, Leuven, Belgium.,Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Sandra Jacobs
- Department of Oncology, KU Leuven, Leuven, Belgium.,Department of Pediatric Hemato-Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Stefan Sunaert
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.,Department of Radiology University Hospitals Leuven, Leuven, Belgium
| | - Charlotte Sleurs
- Department of Oncology, KU Leuven, Leuven, Belgium.,Department of Pediatric Hemato-Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Anne Uyttebroeck
- Department of Oncology, KU Leuven, Leuven, Belgium.,Department of Pediatric Hemato-Oncology, University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
24
|
Ramli N, Lim CH, Rajagopal R, Tan LK, Seow P, Ariffin H. Assessing changes in microstructural integrity of white matter tracts in children with leukaemia following exposure to chemotherapy. Pediatr Radiol 2020; 50:1277-1283. [PMID: 32591982 DOI: 10.1007/s00247-020-04717-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 03/21/2020] [Accepted: 05/12/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Intrathecal and intravenous chemotherapy, specifically methotrexate, might contribute to neural microstructural damage. OBJECTIVE To assess, by diffusion tensor imaging, microstructural integrity of white matter in paediatric patients with acute lymphoblastic leukaemia (ALL) following intrathecal and intravenous chemotherapy. MATERIALS AND METHODS Eleven children diagnosed with de novo ALL underwent MRI scans of the brain with diffusion tensor imaging (DTI) prior to commencement of chemotherapy and at 12 months after diagnosis, using a 3-tesla (T) MRI scanner. We investigated the changes in DTI parameters in white matter tracts before and after chemotherapy using tract-based spatial statistics overlaid on the International Consortium of Brain Mapping DTI-81 atlas. All of the children underwent formal neurodevelopmental assessment at the two study time points. RESULTS Whole-brain DTI analysis showed significant changes between the two time points, affecting several white matter tracts. The tracts demonstrated longitudinal changes of decreasing mean and radial diffusivity. The neurodevelopment of the children was near compatible for age at the end of ALL treatment. CONCLUSION The quantification of white matter tracts changes in children undergoing chemotherapy showed improving longitudinal values in DTI metrics (stable fractional anisotropy, decreasing mean and radial diffusivity), which are incompatible with deterioration of microstructural integrity in these children.
Collapse
Affiliation(s)
- Norlisah Ramli
- Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Jalan Universiti, 50603, Kuala Lumpur, Malaysia.
| | - Chuin Hoong Lim
- Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Jalan Universiti, 50603, Kuala Lumpur, Malaysia
| | - Revathi Rajagopal
- Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Li Kuo Tan
- Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Jalan Universiti, 50603, Kuala Lumpur, Malaysia
| | - Pohchoo Seow
- Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Jalan Universiti, 50603, Kuala Lumpur, Malaysia.,Department of Diagnostic Radiology, Singapore General Hospital, Singapore, Singapore
| | - Hany Ariffin
- Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| |
Collapse
|
25
|
Fellah S, Cheung YT, Scoggins MA, Zou P, Sabin ND, Pui CH, Robison LL, Hudson MM, Ogg RJ, Krull KR. Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia. J Natl Cancer Inst 2020; 111:201-209. [PMID: 29790971 DOI: 10.1093/jnci/djy089] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 03/22/2018] [Accepted: 04/17/2018] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The impact of contemporary chemotherapy treatment for childhood acute lymphoblastic leukemia on central nervous system activity is not fully appreciated. METHODS Neurocognitive testing and functional magnetic resonance imaging (fMRI) were obtained in 165 survivors five or more years postdiagnosis (average age = 14.4 years, 7.7 years from diagnosis, 51.5% males). Chemotherapy exposure was measured as serum concentration of methotrexate following high-dose intravenous injection. Neurocognitive testing included measures of attention and executive function. fMRI was obtained during completion of two tasks, the continuous performance task (CPT) and the attention network task (ANT). Image analysis was performed using Statistical Parametric Mapping software, with contrasts targeting sustained attention, alerting, orienting, and conflict. All statistical tests were two-sided. RESULTS Compared with population norms, survivors demonstrated impairment on number-letter switching (P < .001, a measure of cognitive flexibility), which was associated with treatment intensity (P = .048). Task performance during fMRI was associated with neurocognitive dysfunction across multiple tasks. Regional brain activation was lower in survivors diagnosed at younger ages for the CPT (bilateral parietal and temporal lobes) and the ANT (left parietal and right hippocampus). With higher serum methotrexate exposure, CPT activation decreased in the right temporal and bilateral frontal and parietal lobes, but ANT alerting activation increased in the ventral frontal, insula, caudate, and anterior cingulate. CONCLUSIONS Brain activation during attention and executive function tasks was associated with serum methotrexate exposure and age at diagnosis. These findings provide evidence for compromised and compensatory changes in regional brain function that may help clarify the neural substrates of cognitive deficits in acute lymphoblastic leukemia survivors.
Collapse
Affiliation(s)
- Slim Fellah
- Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN
| | - Yin T Cheung
- Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
| | - Matthew A Scoggins
- Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN
| | - Ping Zou
- Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN
| | - Noah D Sabin
- Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN
| | - Ching-Hon Pui
- Oncology, St. Jude Children's Research Hospital, Memphis, TN
| | - Leslie L Robison
- Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
| | - Melissa M Hudson
- Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN.,Oncology, St. Jude Children's Research Hospital, Memphis, TN
| | - Robert J Ogg
- Departments of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN
| | - Kevin R Krull
- Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
| |
Collapse
|
26
|
DeFeo BM, Kaste SC, Li Z, Brinkman TM, Neel MD, Srivastava DK, Hudson MM, Robison LL, Karol SE, Ness KK. Long-Term Functional Outcomes Among Childhood Survivors of Cancer Who Have a History of Osteonecrosis. Phys Ther 2020; 100:509-522. [PMID: 32044966 PMCID: PMC7246066 DOI: 10.1093/ptj/pzz176] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Revised: 06/17/2019] [Accepted: 09/19/2019] [Indexed: 11/14/2022]
Abstract
BACKGROUND Glucocorticoids used to treat childhood leukemia and lymphoma can result in osteonecrosis, leading to physical dysfunction and pain. Improving survival rates warrants research into long-term outcomes among this population. OBJECTIVE The objective of this study was to compare the physical function and quality of life (QOL) of survivors of childhood cancer who had an osteonecrosis history with that of survivors who had no osteonecrosis history and with that of people who were healthy (controls). DESIGN This was a cross-sectional study. METHODS This study included St Jude Lifetime Cohort Study participants who were ≥ 10 years from the diagnosis of childhood leukemia or lymphoma and ≥ 18 years old; 135 had osteonecrosis (52.5% men; mean age = 27.7 [SD = 6.08] years) and 1560 had no osteonecrosis history (52.4% men; mean age = 33.3 [SD = 8.54] years). This study also included 272 people who were from the community and who were healthy (community controls) (47.7% men; mean age = 35.1 [SD = 10.46] years). The participants completed functional assessments and questionnaires about QOL. RESULTS Survivors with osteonecrosis scored lower than other survivors and controls for dorsiflexion strength (mean score = 16.50 [SD = 7.91] vs 24.17 [SD = 8.61] N·m/kg) and scored lower than controls for flexibility with the sit-and-reach test (20.61 [SD = 9.70] vs 23.96 [SD = 10.73] cm), function on the Physical Performance Test (mean score = 22.73 [SD = 2.05] vs 23.58 [SD = 0.88]), and mobility on the Timed "Up & Go" Test (5.66 [SD = 2.25] vs 5.12 [SD = 1.28] seconds). Survivors with hip osteonecrosis requiring surgery scored lower than survivors without osteonecrosis for dorsiflexion strength (13.75 [SD = 8.82] vs 18.48 [SD = 9.04] N·m/kg), flexibility (15.79 [SD = 8.93] vs 20.37 [SD = 10.14] cm), and endurance on the 6-minute walk test (523.50 [SD = 103.00] vs 572.10 [SD = 102.40] m). LIMITATIONS Because some eligible survivors declined to participate, possible selection bias was a limitation of this study. CONCLUSIONS Survivors of childhood leukemia and lymphoma with and without osteonecrosis demonstrated impaired physical performance and reported reduced QOL compared with controls, with those requiring surgery for osteonecrosis most at risk for impairments. It may be beneficial to provide strengthening, flexibility, and endurance interventions for patients who have pediatric cancer and osteonecrosis for long-term function.
Collapse
Affiliation(s)
- Brian M DeFeo
- DPT, OCS, Rehabilitation Services and Department of Radiological Sciences, Mail Stop 113, St Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis,TN 38105-3678 (USA)
| | - Sue C Kaste
- Department of Radiological Sciences, St Jude Children’s Research Hospital
| | - Zhenghong Li
- Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital
| | - Tara M Brinkman
- Department of Epidemiology and Cancer Control and Department of Psychology, St Jude Children’s Research Hospital
| | - Michael D Neel
- Department of Surgery, St Jude Children’s Research Hospital
| | - Deo Kumar Srivastava
- Department of Biostatistics and Department of Cancer Prevention and Control, St Jude Children’s Research Hospital
| | - Melissa M Hudson
- Department of Epidemiology and Cancer Control, Department of Psychology, Department of Cancer Prevention and Control, and Department of Oncology, St Jude Children’s Research Hospital
| | - Leslie L Robison
- Department of Epidemiology and Cancer Control, Department of Cancer Prevention and Control, and Comprehensive Cancer Center, St Jude Children’s Research Hospital
| | - Seth E Karol
- Department of Oncology and Comprehensive Cancer Center, St Jude Children’s Research Hospital
| | - Kirsten K Ness
- Department of Epidemiology and Cancer Control and Department of Pediatric Medicine, St Jude Children’s Research Hospital
| |
Collapse
|
27
|
Wang L, Zou L, Chen Q, Su L, Xu J, Zhao R, Shan Y, Zhang Q, Zhai Z, Gong X, Zhao H, Tao F, Zheng S. Gray Matter Structural Network Disruptions in Survivors of Acute Lymphoblastic Leukemia with Chemotherapy Treatment. Acad Radiol 2020; 27:e27-e34. [PMID: 31171463 DOI: 10.1016/j.acra.2019.04.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 04/26/2019] [Accepted: 04/28/2019] [Indexed: 01/21/2023]
Abstract
OBJECTIVES Neuroimaging studies of acute lymphoblastic leukemia (ALL) during chemotherapy treatment have shown alterations in structure, function, and connectivity in several brain regions, suggesting neurobiological impairment that might influence the large-scale brain network. This study aimed to detect the alterations in the topological organization of structural covariance networks of ALL patients. METHODS This study included 28 ALL patients undergoing chemotherapy and 20 matched healthy controls. We calculated the gray matter volume of 90 brain regions based on an automated anatomical labeling template and applied graph theoretical analysis to compare the topological parameters of the gray matter structural networks between the two groups. RESULTS The results demonstrated that both the ALL and healthy control groups exhibited a small-world topology across the range of densities. Compared to healthy controls, ALL patients had less highly interactive nodes and a reduced degree/betweenness in temporal regions, which may contribute to impaired memory and executive functions in these patients. CONCLUSION These results reveal that ALL patients undergoing chemotherapy treatment may have decreased regional connectivity and reduced efficiency of their structural covariance network. This is the first report of anomalous large-scale gray matter structural networks in ALL patients undergoing chemotherapy treatment and provides new insights regarding the neurobiological mechanisms underlying the chemo-brain network.
Collapse
Affiliation(s)
- Longsheng Wang
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China; Medical Image Research Center, Anhui Medical University, Hefei, Anhui, China
| | - Liwei Zou
- Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Qi Chen
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Lianzi Su
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Jiajia Xu
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Ru Zhao
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Yanqi Shan
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Qing Zhang
- Department of Hematology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Zhimin Zhai
- Department of Hematology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Xijun Gong
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China; Medical Image Research Center, Anhui Medical University, Hefei, Anhui, China
| | - Hong Zhao
- Department of Radiology, the Second Hospital of Anhui Medical University, Hefei, Anhui, China; Medical Image Research Center, Anhui Medical University, Hefei, Anhui, China
| | - Fangbiao Tao
- Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, Hefei, Anhui, China; Anhui Provincial Key Laboratory of Population Health and Aristogenics, Hefei, Anhui, China.
| | - Suisheng Zheng
- Ping An Healthcare Diagnostics Center, Hefei, Anhui, China.
| |
Collapse
|
28
|
Zhou C, Zhuang Y, Lin X, Michelson AD, Zhang A. Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. Br J Haematol 2019; 188:945-961. [PMID: 31823355 DOI: 10.1111/bjh.16279] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 09/18/2019] [Indexed: 12/25/2022]
Abstract
Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children. Although the survival rate has increased dramatically over the last decades, patients struggle with the adverse side effects of treatment. Treatment for ALL includes chemotherapy and irradiation - both of which are linked to cognitive impairments and alterations in central nervous system (CNS) structure and function detected by neuroimaging and in neurocognitive studies. The present article is a meta-analysis of the existing evidence for the mechanisms underlying changes in the CNS and neurocognitive function in ALL survivors after treatment. We found that compared with controls, ALL survivors develop: (i) cognitive sequelae in intelligence, academics, attention, memory, processing speed and executive function domains; (ii) decreased grey and white matter volume in cortical and several subcortical brain regions, with functional changes particularly in frontal regions and the hippocampus; (iii) neurocognitive impairments related to CNS changes; and (iv) reduction, but not resolution, of late neurocognitive sequelae in patients in whom prophylactic irradiation was replaced by systemic/intrathecal chemotherapy. Continued work with advanced functional magnetic resonance imaging techniques will hopefully allow the detection of early CNS changes as biomarkers to help guide early diagnosis and intervention for neurocognitive defects in patients with childhood ALL.
Collapse
Affiliation(s)
- Chendan Zhou
- Department of Pediatrics, Qilu Hospital, Shandong University, Jinan, Shandong, China
| | - Yong Zhuang
- Department of Pediatrics, Qilu Hospital, Shandong University, Jinan, Shandong, China
| | - Xingjie Lin
- Department of Pediatrics, Qilu Hospital, Shandong University, Jinan, Shandong, China
| | - Alan D Michelson
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA
| | - Aijun Zhang
- Department of Pediatrics, Qilu Hospital, Shandong University, Jinan, Shandong, China.,Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
29
|
A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. Pediatr Neurol 2019; 101:2-10. [PMID: 31047756 DOI: 10.1016/j.pediatrneurol.2019.03.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Revised: 02/11/2019] [Accepted: 03/08/2019] [Indexed: 10/27/2022]
Abstract
Currently, there are an estimated 400,000 long-term survivors of childhood cancer in the United States. Chronic leukoencephalopathy is a potential devastating late effect that can manifest as a range of neurological and neurocognitive sequelae. Survivors of the acute lymphocytic leukemia, central nervous system tumors, and stem cell transplant have frequently been exposed to cranial radiation, systemic and intrathecal chemotherapy, which places them at risk of developing chronic leukoencephalopathy. Defining leukoencephalopathy and its neuroimaging characteristics, the population of survivors at risk, its long-term consequences, and identifying prevention and intervention strategies can potentially mitigate the morbidity of these survivors. Better understanding of those at risk of leukoencephalopathy and its symptoms can lead to an improved quality of life for these cancer survivors.
Collapse
|
30
|
Brace KM, Lee WW, Cole PD, Sussman ES. Childhood leukemia survivors exhibit deficiencies in sensory and cognitive processes, as reflected by event-related brain potentials after completion of curative chemotherapy: A preliminary investigation. J Clin Exp Neuropsychol 2019; 41:814-831. [PMID: 31156064 PMCID: PMC6663575 DOI: 10.1080/13803395.2019.1623865] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 05/20/2019] [Indexed: 10/26/2022]
Abstract
Objective: The purpose of this study was to characterize post-chemotherapy sensory, memory, and attention abilities in childhood survivors of acute lymphoblastic leukemia (ALL) to better understand how treatment affects cognitive functioning. Methods: Eight ALL survivors and eight age-matched, healthy children between the ages of 5-11 years participated in the study. Among the ALL survivors, a median of 63 days (range 22-267 days) elapsed between completion of chemotherapy and this assessment. Sounds were presented in an oddball paradigm while recording the electroencephalogram in separate conditions of passive listening and active task performance. To assess different domains of cognition, we measured event-related brain potentials (ERPs) reflecting sensory processing (P1 component), working memory (mismatch negativity [MMN] component), attentional orienting (P3a), and target detection (P3b component) in response to the sounds. We also measured sound discrimination and response speed performance. Results: Relative to control subjects, ALL survivors had poorer performance on auditory tasks, as well as decreased amplitude of the P1, MMN, P3a, and P3b components. ALL survivors also did not exhibit the amplitude gain typically observed in the sensory P1 component when attending to the sound input compared to when passively listening. Conclusions: Atypical responses were observed in brain processes associated with sensory discrimination, auditory working memory, and attentional control in pediatric ALL survivors indicating deficiencies in all cognitive domains compared to age-matched controls. Significance: ERPs differentiated aspects of cognitive functioning, which may provide a useful tool for assessing recovery and risk of post-chemotherapy cognitive deficiencies in young children. The decreased MMN amplitude in ALL survivors may indicate (N-methyl D-aspartate) NMDA dysfunction induced by methotrexate, and thus provides a potential therapeutic target for chemotherapy-associated cognitive impairments.
Collapse
Affiliation(s)
- Kelin M. Brace
- Department of Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
| | - Wei Wei Lee
- Department of Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
| | - Peter D. Cole
- Department of Pediatrics, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United States
| | - Elyse S. Sussman
- Department of Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
- Department of Otorhinolaryngology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
| |
Collapse
|
31
|
Sleurs C, Lemiere J, Radwan A, Verly M, Elens I, Renard M, Jacobs S, Sunaert S, Deprez S, Uyttebroeck A. Long-term leukoencephalopathy and neurocognitive functioning in childhood sarcoma patients treated with high-dose intravenous chemotherapy. Pediatr Blood Cancer 2019; 66:e27893. [PMID: 31276297 DOI: 10.1002/pbc.27893] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 06/07/2019] [Accepted: 06/10/2019] [Indexed: 12/11/2022]
Abstract
PURPOSE Knowledge is limited regarding the prevalence and persistence of chemotherapy-induced leukoencephalopathy in childhood sarcoma patients. This study explored the presence, clinical relevance, and potential risk factors of leukoencephalopathy in childhood bone and soft tissue sarcoma survivors, treated with intravenous chemotherapy. METHODS We acquired cross-sectional neurocognitive data in adult survivors (n = 34) (median age at diagnosis [AaD] = 13.32 years, age range = 16-35 years) and healthy age-matched controls (n = 34). Additionally, magnetic resonance imaging included T2-weighted FLAIR (leukoencephalopathy Fazekas rating), multiexponential T2 relaxation (MET2), and multishell diffusion MRI to estimate myelin integrity-related metrics and fluid movement restrictions. Finally, chemotherapy subgroups (methotrexate, alkylating agents, or combination), AaD, and Apoε and MTHFRC677T polymorphisms were explored as potential risk factors for leukoencephalopathy. RESULTS At the group level, quality of life, working memory, processing speed, and visual memory were significantly lower in patients compared to controls. Furthermore, long-term leukoencephalopathy was observed in 27.2% of the childhood sarcoma survivors, which was related to attentional processing speed. Lesions were related to diffusion-derived, but not to myelin-sensitive metrics. A significant interaction effect between AaD and chemotherapy group demonstrated more lesions in case of high-dose methotrexate (HD-MTX) (F = 3.434, P = .047). However, patients treated with alkylating agents (without HD-MTX) also showed lesions in younger patients. Genetic predictors were nonsignificant. CONCLUSION AND IMPLICATION This study suggests long-term leukoencephalopathy with possibly underlying changes in vasculature, inflammation, or axonal injury, but not necessarily long-term demyelination. Such lesions could affect processing speed, and as such long-term daily life functioning of these patients.
Collapse
Affiliation(s)
- Charlotte Sleurs
- Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
- Department of Oncology, KU Leuven, Leuven, Belgium
| | - Jurgen Lemiere
- Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Ahmed Radwan
- Department of Radiology, University Hospital Leuven, Leuven, Belgium
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | | | - Iris Elens
- Department of Biological Psychology, KU Leuven, Belgium
| | - Marleen Renard
- Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
| | - Sandra Jacobs
- Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
- Department of Oncology, KU Leuven, Leuven, Belgium
| | - Stefan Sunaert
- Department of Radiology, University Hospital Leuven, Leuven, Belgium
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Sabine Deprez
- Department of Radiology, University Hospital Leuven, Leuven, Belgium
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Anne Uyttebroeck
- Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium
- Department of Oncology, KU Leuven, Leuven, Belgium
| |
Collapse
|
32
|
Billiet T, Elens I, Sleurs C, Uyttebroeck A, D'Hooge R, Lemiere J, Deprez S. Brain Connectivity and Cognitive Flexibility in Nonirradiated Adult Survivors of Childhood Leukemia. J Natl Cancer Inst 2019. [PMID: 29514304 DOI: 10.1093/jnci/djy009] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background This study aimed to assess functional and structural brain connectivity in adult childhood leukemia survivors and the link with cognitive functioning and previously identified risk factors such as intrathecal methotrexate dose and age at start of therapy. Methods Thirty-one nonirradiated adult childhood leukemia survivors and 35 controls underwent cognitive testing and multimodal magnetic resonance imaging (resting state functional MRI, T1-weighted, diffusion-weighted, and myelin water imaging [MWI]). Analyses included dual regression, voxel-based morphometry, advanced diffusion, and MWI modeling techniques besides stepwise discriminant function analysis to identify the most affected executive cognitive domain. Correlations with discrete intrathecal MTX doses and (semi)continuous variables were calculated using Spearman's rank and Pearson's correlation, respectively. All correlation tests were two-sided. Positive and negative T-contrasts in functional and structural MRI analysis were one-sided. Results Survivors demonstrated lower functional connectivity between the default mode network (DMN) and inferior temporal gyrus (ITG; P < .008). Additionally, we observed higher fractional anisotropy (FA; P = .04) and lower orientation dispersion index (ODI; P = .008) at the left centrum semiovale, which could-given that several fiber bundles cross this region-suggest selective reduced integrity of the respective white matter tracts. Set shifting reaction time, a measure of cognitive flexibility, was mostly impaired and correlated with lower FA (r = -0.53, P = .003) and higher ODI (r = 0.40, P = .04) in survivors but not with DMN-ITG connectivity. There were no statistically significant differences between survivors and controls in WM or GM volume, nor was there a statistically significant correlation between imaging measurements and age at start of therapy or intrathecal methotrexate dose. Conclusions Adult, nonirradiated childhood leukemia survivors show altered brain connectivity, which is linked with cognitive flexibility.
Collapse
Affiliation(s)
- Thibo Billiet
- Department of Radiology, University Hospital Leuven, Leuven, Belgium.,Icometrix, Leuven, Belgium
| | - Iris Elens
- Department of Child and Adolescent Psychiatry, KU Leuven, University Psychiatric Centre Leuven, Leuven, Belgium.,Laboratory of Biological Psychology, KU Leuven, Leuven, Belgium
| | - Charlotte Sleurs
- Department of Radiology, University Hospital Leuven, Leuven, Belgium.,Department of Pediatrics, Pediatric Hemato-Oncology, KU Leuven, University Hospital Leuven, Leuven, Belgium
| | - Anne Uyttebroeck
- Department of Pediatrics, Pediatric Hemato-Oncology, KU Leuven, University Hospital Leuven, Leuven, Belgium
| | - Rudi D'Hooge
- Laboratory of Biological Psychology, KU Leuven, Leuven, Belgium
| | - Jurgen Lemiere
- Department of Pediatrics, Pediatric Hemato-Oncology, KU Leuven, University Hospital Leuven, Leuven, Belgium
| | - Sabine Deprez
- Department of Radiology, University Hospital Leuven, Leuven, Belgium.,Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| |
Collapse
|
33
|
Follin C, Svärd D, van Westen D, Björkman-Burtscher IM, Sundgren PC, Fjalldal S, Lätt J, Nilsson M, Johanson A, Erfurth EM. Microstructural white matter alterations associated to neurocognitive deficits in childhood leukemia survivors treated with cranial radiotherapy - a diffusional kurtosis study. Acta Oncol 2019; 58:1021-1028. [PMID: 30747019 DOI: 10.1080/0284186x.2019.1571279] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Background: Cranial radiotherapy (CRT) is a known risk factor for neurocognitive impairment in survivors of childhood acute lymphoblastic leukemia (ALL). Diffusion tensor imaging (DTI) and diffusional kurtosis imaging (DKI) are MRI techniques that quantify microstructural changes in brain white matter (WM) and DKI is regarded as the more sensitive of them. Our aim was to more thoroughly understand the nature of cognitive deficits after cranial radiotherapy (CRT) in adulthood after childhood ALL. Material and methods: Thirty-eight (21 women) ALL survivors, median age 38 (27-46) years, were investigated at median 34 years after diagnosis. All had been treated with a CRT dose of 24 Gy and with 11 years of complete hormone supplementation. DTI and DKI parameters were determined and neurocognitive tests were performed in ALL survivors and 29 matched controls. Results: ALL survivors scored lower than controls in neurocognitive tests of vocabulary, memory, learning capacity, spatial ability, executive functions, and attention (p < .001). The survivors had altered DTI parameters in the fornix, uncinate fasciculus, and ventral cingulum (all p < .05) and altered DKI parameters in the fornix, uncinate fasciculus, and dorsal and ventral cingulum (p < .05). Altered DTI parameters in the fornix were associated with impaired episodic verbal memory (r = -0.40, p < .04). The left and right uncinate fasciculus (r = 0.6, p < .001), (r = -0.5, p < .02) as well as the right ventral cingulum (r = 0.5, p < .007) were associated with impaired episodic visual memory. Altered DKI parameters in the fornix, right uncinate fasciculus (r = 0.3, r = 0.05, p = .02), and ventral cingulum (r = 0.3, p = .02) were associated with impaired results of episodic visual memory. Conclusion: ALL survivors with cognitive deficits demonstrated microstructural damage in several WM tracts that were more extensive with DKI as compared to DTI; this might be a marker of radiation and chemotherapy neurotoxicity underlying cognitive dysfunction.
Collapse
Affiliation(s)
- Cecilia Follin
- Department of Oncology, Skåne University Hospital and IKVL, Lund University, Lund, Sweden
| | - Daniel Svärd
- Department of Diagnostic Radiology, Skåne University Hospital and Clinical Sciences, Lund University, Lund, Sweden
- Department of Clinical Sciences and Radiology, Faculty of Medicine, Lund University, Lund, Sweden
| | - Danielle van Westen
- Department of Diagnostic Radiology, Skåne University Hospital and Clinical Sciences, Lund University, Lund, Sweden
- Department of Clinical Sciences and Radiology, Faculty of Medicine, Lund University, Lund, Sweden
| | - Isabella M. Björkman-Burtscher
- Department of Diagnostic Radiology, Skåne University Hospital and Clinical Sciences, Lund University, Lund, Sweden
- Lund University Bioimaging Center, Lund University, Lund, Sweden
| | - Pia C. Sundgren
- Department of Diagnostic Radiology, Skåne University Hospital and Clinical Sciences, Lund University, Lund, Sweden
| | - Sigridur Fjalldal
- Department of Endocrinology, Skåne University hospital, Lund, Sweden
| | - Jimmy Lätt
- Department of Diagnostic Radiology, Skåne University Hospital and Clinical Sciences, Lund University, Lund, Sweden
| | - Markus Nilsson
- Department of Diagnostic Radiology, Skåne University Hospital and Clinical Sciences, Lund University, Lund, Sweden
| | - Aki Johanson
- Department of Psychiatry, Clinical Sciences, Lund University, Lund, Sweden
| | - Eva Marie Erfurth
- Department of Endocrinology, Skåne University hospital, Lund, Sweden
| |
Collapse
|
34
|
Elens I, Deprez S, Danckaerts M, Bijttebier P, Labarque V, Uyttebroeck A, Van Gool S, D'Hooge R, Lemiere J. Neurocognitive Sequelae in Adult Childhood Leukemia Survivors Related to Levels of Phosphorylated Tau. J Natl Cancer Inst 2019; 109:3739023. [PMID: 29982754 DOI: 10.1093/jnci/djw321] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 12/05/2016] [Indexed: 01/03/2023] Open
Abstract
Central nervous system-directed prophylactic chemotherapy increases survival in childhood leukemia, but possible late neurocognitive sequelae remain a concern. We compared intellectual performance (WAIS IV), memory (AVLT), and executive functioning (ANT) between adult leukemia survivors (n = 31) and control individuals (n = 35). In survivors, cerebrospinal fluid (CSF) levels of phosphorylated Tau (p-Tau) during treatment and total intrathecal methotrexate dose correlated with adult intellectual performance (Pearson's and Spearman's coefficients, respectively). Long-term memory and attentional control, both maturing before survivors' mean age at diagnosis, were unaffected (P > .05 on all four subtests), in contrast to cognitive flexibility and information processing (P < .05 for eight of the subtests), which mature during adolescence. CSF p-Tau and methotrexate dose negatively correlated with intellectual performance (r = -0.414, P = .04 and r = -0.484, P = .007, respectively), but not with each other (r = 0.219, P = .29). These data identify CSF p-Tau as a predictor of late neurocognitive sequelae (in addition to methotrexate dose). Early identification of children at risk could inspire interventions to prevent or remediate chemotherapy-induced cognitive sequelae.
Collapse
Affiliation(s)
- Iris Elens
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Sabine Deprez
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Marina Danckaerts
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Patricia Bijttebier
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Veerle Labarque
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Anne Uyttebroeck
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Stefaan Van Gool
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Rudi D'Hooge
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| | - Jurgen Lemiere
- Affiliations of authors: Laboratory of Biological Psychology (IE, RDH), Department of Imaging and Pathology (SD), Department of School Psychology and Child and Adolescent Development (PB), Department of Pediatrics, Pediatric Hemato-Oncology (VL, AU, JL), Department of Cardiovascular Medicine (VL), and Department of Child and Adolescent Psychiatry, University Psychiatric Centre Leuven (IE, MD, JL), KU Leuven, Leuven, Belgium; Department of Radiology, University Hospital Leuven, Leuven, Belgium (SD); Immunologisch Onkologisches Zentrum Köln, Köln, Germany (SVG)
| |
Collapse
|
35
|
Mulrooney DA, Hyun G, Ness KK, Bhakta N, Pui CH, Ehrhardt MJ, Krull KR, Crom DB, Chemaitilly W, Srivastava DK, Relling MV, Jeha S, Green DM, Yasui Y, Robison LL, Hudson MM. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. LANCET HAEMATOLOGY 2019; 6:e306-e316. [PMID: 31078468 DOI: 10.1016/s2352-3026(19)30050-x] [Citation(s) in RCA: 83] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 02/16/2019] [Accepted: 02/19/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND Treatment for childhood acute lymphoblastic leukemia has evolved over the past five decades, with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies. The affect of these changes on late health outcomes has not been assessed. Using data from the The St Jude Lifetime (SJLIFE) Cohort, we aimed to characterise the magnitude of morbidity and patterns of late health outcomes among survivors of childhood acute lymphoblastic leukaemia treated over time. METHODS The St Jude Lifetime (SJLIFE) Cohort is a retrospective cohort study with prospective follow-up and ongoing data accrual designed to facilitate longitudinal, clinically-based assessment of health outcomes among survivors of paediatric malignancies. 980 survivors included in this analysis were diagnosed with paediatric acute lymphoblastic leukaemia at St Jude Children's Research Hospital (SJCRH) between Aug 28, 1963, and July 19, 2003, were aged 18 years old and older at enrolment, had a minimum follow-up of 10 years after diagnosis, and completed an initial on-campus SJLIFE assessment as of data cutoff (June 30, 2015). 272 community control participants, matched to survivors on 5-year age blocks in each sex, were recruited for comparison. Cumulative chemotherapy and radiation dose exposures and major medical events during and after therapy were retrieved from the medical records of the survivors. History or physical examination, laboratory analysis, physical fitness, and neurocognitive testing were done. Health conditions were graded according to a modified version of the Common Terminology Criteria for Adverse Events. Neurocognitive domains of attention (Trial Making Test Part A and Conner's Continuous Performance Test-II) and executive function (Trail Making Test Part B, Controlled Oral Word Association Test, and Wechsler Adult Intelligence Scale-III Digit Span Test Backward) were measured and age-adjusted Z scores were calculated. Mean cumulative count was used to calculate the age-standardised cumulative burden of health conditions over time. This cohort study is registered at ClinicalTrials.gov, number NCT00760656. FINDINGS 980 survivors of acute lymphoblastic leukaemia (50% women, median age at diagnosis 5 years [IQR 3·1-9·1 years], and median time from diagnosis of 30·0 years [22·7-36·3]) had a median age of 35·8 years (29·4-42·9) at assessment compared with 35·1 years (28·7-42·6) for 272 controls. Survivors had significantly more growth hormone deficiency, hypogonadism, and neuropathy than controls. By age 30 years, survivors of acute lymphoblastic leukaemia had, on average, 5·4 (95% CI 5·1-5·8) grade 1-4 health conditions, including 3·2 (2·9-3·4) grade 2-4 health conditions, compared with 2·0 (CI 1·7-2·2) grade 1-4 and 1·2 (1·03-1·4) grade 2-4 health conditions among controls. The cumulative burden of grade 2-4 health conditions involved multiple organ systems for survivors treated on protocols between 1962-91, but after elimination of cranial radiotherapy for children with acute lymphoblastic leukaemia, conditions now predominately include musculoskeletal and endocrine disorders for survivors on protocols between 1991-2007. INTERPRETATION Although changes in paediatric acute lymphoblastic leukaemia treatment protocols have improved overall survival, the burden of late morbidity remains high for these patients. We show that the pattern of late toxic effects has markedly changed over time, with survivors having a reduction in health conditions that are immediately life-threatening, however, maintaining health status and quality of life for survivors of paediatric acute lymphoblastic leukaemia requires continued medical surveillance, counselling, and lifestyle modifications. FUNDING US National Cancer Institute and the American Lebanese Syrian Associated Charities.
Collapse
Affiliation(s)
- Daniel A Mulrooney
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Departments of Pediatrics and Medicine, University of Tennessee Health Science Center, College of Medicine, Memphis, TN, USA.
| | - Geehong Hyun
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Kirsten K Ness
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Nickhill Bhakta
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Ching-Hon Pui
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Matthew J Ehrhardt
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Kevin R Krull
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Psychology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Deborah B Crom
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Wassim Chemaitilly
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA
| | | | - Mary V Relling
- Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Sima Jeha
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Daniel M Green
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Yutaka Yasui
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Leslie L Robison
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Melissa M Hudson
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Departments of Pediatrics and Medicine, University of Tennessee Health Science Center, College of Medicine, Memphis, TN, USA
| |
Collapse
|
36
|
Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration. JOURNAL OF ONCOLOGY 2019; 2019:3283629. [PMID: 31186631 PMCID: PMC6521476 DOI: 10.1155/2019/3283629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Accepted: 04/09/2019] [Indexed: 02/05/2023]
Abstract
Background For childhood acute lymphocytic leukemia (ALL), central nervous system leukemia (CNSL) is still the main reason of treatment failure. Changes of cerebrospinal fluid (CSF) proteome are deemed to occur after intrathecal chemotherapy. Objective To find critical CSF biomarkers, which could be utilized to increase diagnostic and prognostic accuracy of CNSL. Methods We performed proteomic profiling of CSF before and after the treatment of six sporadic paediatric patients diagnosed as ALL with central nervous system (CNS) involvement. CSF samples were properly processed and analyzed through the use of label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results Among identified 428 unique proteins in all CSF samples, we quantified 10 altered proteins with diverse biological functions after induction chemotherapy. Conclusions The levels of those 10 proteins change during the treatment of CNSL. Some of the proteins are likely to play a vital biological role as biomarkers for the development of ALL. In addition, our results indicated the feasible and reproducible utility of CSF for diagnosis and prognosis of patients with CNSL.
Collapse
|
37
|
Abstract
PURPOSE OF REVIEW The advent of proton beam therapy (PBT) has initiated a paradigm shift in the field of pediatric radiation oncology, with increasing promise to alleviate both short-term and long-term toxicities. Given the dramatic rise in proton therapy centers in the United States, a discussion of the quality of evidence supporting its use in pediatric cancers is warranted. RECENT FINDINGS Proton radiotherapy appears to decrease the incidence and severity of late effects with the strongest evidence in pediatric brain tumor cohorts that shows benefits in neurocognitive, hearing, and endocrine outcomes. However, emerging data has shown that more conservative brainstem dose limits with protons compared with photons are required to limit brainstem toxicity; these modified recommendations have been incorporated into national cooperative group studies. Decreased toxicity in tumors outside of the CNS for PBT have also been reported in sarcomas, Hodgkin disease and neuroblastoma. Similarly, QoL outcomes are improved in brain tumor and other cohorts of patients treated with PBT. SUMMARY The collective findings demonstrate improved understanding and refinement of PBT in pediatric cancers. Data on QOL, toxicity and disease outcomes with PBT should continue to be collected and reported in order to understand the full extent of the risks and benefits associated with PBT.
Collapse
|
38
|
Ólafsdóttir IM, Gestsdóttir S, Kristjánsson Á. Visual foraging and executive functions: A developmental perspective. Acta Psychol (Amst) 2019; 193:203-213. [PMID: 30660998 DOI: 10.1016/j.actpsy.2019.01.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 12/21/2018] [Accepted: 01/07/2019] [Indexed: 10/27/2022] Open
Abstract
Visual foraging tasks, where participants search for multiple targets at a time, may provide a richer picture of visual attention than traditional single-target visual search tasks. To contribute to the mapping of foraging abilities throughout childhood and to assess whether foraging ability is dependent upon EF abilities, we compared the foraging of 66 children aged 4-7 years (mean age = 5.68 years, SD = 0.97 years, 33 girls), 67 children aged 11-12 years (mean age = 11.80 years, SD = 0.30 years; 36 girls), and 31 adults aged 20-37 (mean age 30.32 years, SD 4.37 years, 18 females) in Iceland, with a task involving multiple targets of different types. We also measured three subdomains of executive functions; inhibition, attentional flexibility, and working memory. Our results show that foraging improves dramatically between the preschool and middle school years, with the older children showing similar foraging abilities as adults due to greater ease of switching between target types. The older children and adults randomly switch between target templates during feature foraging, but exhaustively forage for a single target type before switching during conjunction foraging. Younger children, conversely, tended to also stick to the same target type for long runs during feature foraging, showing that they have difficulties with feature-based tasks. Switch costs were much lower for the older children than the youngest age group, and on par with those of adults, resulting in fast and efficient foraging. Lastly, we found a connection between foraging ability and both working memory and attentional flexibility, but not inhibition. Our study shows that foraging is a promising way of studying visual attention, how it changes throughout the lifespan, and how it is connected to other cognitive functions.
Collapse
|
39
|
Krull KR, Li C, Phillips NS, Cheung YT, Brinkman TM, Wilson CL, Armstrong GT, Khan RB, Merchant TE, Sabin ND, Srivastava D, Pui CH, Robison LL, Hudson MM, Sklar CA, Chemaitilly W. Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2019; 125:1748-1755. [PMID: 30690723 DOI: 10.1002/cncr.31975] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 12/11/2018] [Accepted: 12/12/2018] [Indexed: 11/06/2022]
Abstract
BACKGROUND The impact of growth hormone deficiency (GHD) on neurocognitive function is poorly understood in survivors of childhood acute lymphoblastic leukemia (ALL). This study examined the contribution of GHD to functional outcomes while adjusting for cranial radiation therapy (CRT). METHODS Adult survivors of ALL (N = 571; 49% female; mean age, 37.4 years; age range, 19.4-62.2 years) completed neurocognitive tests and self-reported neurocognitive symptoms, emotional distress, and quality of life. GHD was defined as a previous diagnosis of GHD or a plasma insulin-like growth factor1 level less than -2.0 standard deviations for sex and age at the time of neurocognitive testing. Hypothyroidism, hypogonadism, sex, age at diagnosis, CRT dose, and intrathecal and high-dose intravenous methotrexate were included as covariates in multivariable linear regression models. RESULTS Of the 571 survivors, 298 (52%) had GHD, and those with GHD received higher doses of CRT (P = .002). Survivors who had GHD, irrespective of prior growth hormone treatment, demonstrated poorer vocabulary (z-score, -0.84 vs -0.61; P = .02), processing speed (z-score, -0.49 vs -0.30; P = .04), cognitive flexibility (z-score, -1.37 vs -0.94; P = .01), and verbal fluency (z-score, -0.74 vs -0.44; P = .001), and they self-reported more neurocognitive problems and poorer quality of life compared with survivors who did not have GHD. Multivariable and mediation models revealed that GHD was associated with small effects on quality of life (general health, P = .01; vitality, P = .01; mental health, P = .01); and CRT dose accounted for the lower neurocognitive outcomes. CONCLUSIONS Adult survivors of childhood ALL who receive CRT are at risk for GHD, although poor neurocognitive outcomes are determined by CRT dose and not by the presence of GHD.
Collapse
Affiliation(s)
- Kevin R Krull
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.,Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Chenghong Li
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Nicholas S Phillips
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Yin Ting Cheung
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.,School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
| | - Tara M Brinkman
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.,Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Carmen L Wilson
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Gregory T Armstrong
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Raja B Khan
- Department of Pediatric Medicine, Division of Neurology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Thomas E Merchant
- Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Noah D Sabin
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - DeoKumar Srivastava
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Ching-Hon Pui
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Leslie L Robison
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Melissa M Hudson
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.,Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Charles A Sklar
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Wassim Chemaitilly
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.,Department of Pediatric Medicine, Division of Endocrinology, St. Jude Children's Research Hospital, Memphis, Tennessee
| |
Collapse
|
40
|
Bargiotas I, Moreau A, Vienne A, Bompaire F, Baruteau M, de Laage M, Campos M, Psimaras D, Vayatis N, Labourdette C, Vidal PP, Ricard D, Buffat S. Balance Impairment in Radiation Induced Leukoencephalopathy Patients Is Coupled With Altered Visual Attention in Natural Tasks. Front Neurol 2019; 9:1185. [PMID: 30728804 PMCID: PMC6351469 DOI: 10.3389/fneur.2018.01185] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2018] [Accepted: 12/21/2018] [Indexed: 12/02/2022] Open
Abstract
Background: Recent studies have shown that alterations in executive function and attention lead to balance control disturbances. One way of exploring the allocation of attention is to record eye movements. Most experimental data come from a free viewing of static scenes but additional information can be leveraged by recording eye movements during natural tasks. Here, we aimed to provide evidence of a correlation between impaired visual alteration in natural tasks and postural control in patients suffering from Radiation-Induced Leukoencephalopathy (RIL). Methods: The study subjects were nine healthy controls and 10 patients who were diagnosed with RIL at an early stage, with isolated dysexecutive syndrome without clinically detectable gait or posture impairment. We performed a balance evaluation and eye movement recording during an ecological task (reading a recipe while cooking). We calculated a postural score and oculomotor parameters already proposed in the literature. We performed a variable selection using an out-of-bag random permutation and a random forest regression algorithm to find: (i) if visual parameters can predict postural deficit and, (ii) which are the most important of them in this prediction. Results were validated using the leave-one-out cross-validation procedure. Results: Postural scores indeed were found significantly lower in patients with RIL than in healthy controls. Visual parameters were found able to predict the postural score of RIL patients with normalized root mean square error (RMSE) of 0.16. The present analysis showed that horizontal and vertical eye movements, as well as the average duration of the saccades and fixations influenced significantly the prediction of the postural score in RIL patients. While two patients with very low MATTIS-Attention sub score showed the lowest postural scores, no statistically significant relationship was found between the two outcomes. Conclusion: These results highlight the significant relationship between the severity of balance deficits and the visual characteristics in RIL patients. It seems that increased balance impairment is coupled with a reduced focusing capacity in ecological tasks. Balance and eye movement recordings during a natural task could be a useful aspect of multidimensional scoring of the dysexecutive syndrome.
Collapse
Affiliation(s)
- Ioannis Bargiotas
- UMR 8257 Cognition and Action Group (CNRS, Service de Santé des Armées, Université Paris Descartes Paris Sorbonne Cité), Paris, France.,CMLA, ENS Cachan, CNRS, Université Paris-Saclay, Cachan, France
| | - Albane Moreau
- Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France
| | - Alienor Vienne
- UMR 8257 Cognition and Action Group (CNRS, Service de Santé des Armées, Université Paris Descartes Paris Sorbonne Cité), Paris, France
| | - Flavie Bompaire
- Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France.,OncoNeuroTox Center, Paris, France
| | - Marie Baruteau
- Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France.,OncoNeuroTox Center, Paris, France
| | - Marie de Laage
- Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France
| | - Matéo Campos
- Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France
| | - Dimitri Psimaras
- Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France.,OncoNeuroTox Center, Paris, France
| | - Nicolas Vayatis
- CMLA, ENS Cachan, CNRS, Université Paris-Saclay, Cachan, France
| | | | - Pierre-Paul Vidal
- UMR 8257 Cognition and Action Group (CNRS, Service de Santé des Armées, Université Paris Descartes Paris Sorbonne Cité), Paris, France.,School of Automation, Hangzhou Dianzi University, Zhejiang, China
| | - Damien Ricard
- UMR 8257 Cognition and Action Group (CNRS, Service de Santé des Armées, Université Paris Descartes Paris Sorbonne Cité), Paris, France.,Service de neurologie, Hôpital d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France.,OncoNeuroTox Center, Paris, France.,Ecole du val de Grâce, Service de Santé des Armées, Paris, France
| | - Stéphane Buffat
- UMR 8257 Cognition and Action Group (CNRS, Service de Santé des Armées, Université Paris Descartes Paris Sorbonne Cité), Paris, France.,OncoNeuroTox Center, Paris, France.,Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France
| |
Collapse
|
41
|
Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Holohan Nudelman K, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, Ahles T. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. J Clin Oncol 2018; 36:JCO1800140. [PMID: 30281396 PMCID: PMC7237199 DOI: 10.1200/jco.18.00140] [Citation(s) in RCA: 111] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. METHODS Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that measured attention, processing speed, and executive function (APE) and learning and memory (LM). Linear mixed-effects models tested two-way interactions of treatment group (control, chemotherapy with or without hormonal therapy, and hormonal therapy) and time and explored three-way interactions of ApoE (ε4+ v not) by group by time; covariates included baseline age, frailty, race, and cognitive reserve. RESULTS Survivors and controls were 60 to 98 years of age, were well educated, and had similar baseline cognitive scores. Treatment was related to longitudinal cognition scores, with survivors who received chemotherapy having increasingly worse APE scores ( P = .05) and those initiating hormonal therapy having lower LM scores at 12 months ( P = .03) than other groups. These group-by-time differences varied by ApoE genotype, where only ε4+ survivors receiving hormone therapy had short-term decreases in adjusted LM scores (three-way interaction P = .03). For APE, the three-way interaction was not significant ( P = .14), but scores were significantly lower for ε4+ survivors exposed to chemotherapy (-0.40; 95% CI, -0.79 to -0.01) at 24 months than ε4+ controls (0.01; 95% CI, 0.16 to 0.18; P < .05). Increasing age was associated with lower baseline scores on all cognitive measures ( P < .001); frailty was associated with baseline APE and self-reported decline ( P < .001). CONCLUSION Breast cancer systemic treatment and aging-related phenotypes and genotypes are associated with longitudinal decreases in cognitive function scores in older survivors. These data could inform treatment decision making and survivorship care planning.
Collapse
Affiliation(s)
- Jeanne S. Mandelblatt
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Brent J. Small
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Gheorghe Luta
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Arti Hurria
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Heather Jim
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Brenna C. McDonald
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Deena Graham
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Xingtao Zhou
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Jonathan Clapp
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Wanting Zhai
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Elizabeth Breen
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Judith E. Carroll
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Neelima Denduluri
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Asma Dilawari
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Martine Extermann
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Claudine Isaacs
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Paul B. Jacobsen
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Lindsay C. Kobayashi
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Kelly Holohan Nudelman
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - James Root
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Robert A. Stern
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Danielle Tometich
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Raymond Turner
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - John W. VanMeter
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Andrew J. Saykin
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| | - Tim Ahles
- Jeanne S. Mandelblatt, Gheorghe Luta, Xingtao Zhou, Jonathan Clapp, Wanting Zhai, Asma Dilawari, Claudine Isaacs, Lindsay C. Kobayashi, Raymond Turner, and John W. VanMeter, Georgetown University; Asma Dilawari, MedStar Washington Hospital Center, Washington, DC; Brent J. Small, Heather Jim, and Martine Extermann, Moffitt Cancer Center, Tampa, FL; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte; Elizabeth Breen and Judith E. Carroll, University of California, Los Angeles, Los Angeles, CA; Brenna C. McDonald, Kelly Holohan Nudelman, Danielle Tometich, and Andrew J. Saykin, Indiana University School of Medicine, Indianapolis, IN; Deena Graham, John Theurer Cancer Center, Hackensack, NJ; Neelima Denduluri, US Oncology, Arlington, VA; Paul B. Jacobsen, National Cancer Institute, Bethesda, MD; James Root and Tim Ahles, Memorial Sloan Kettering Cancer Center; James Root, Weill Medical College of Cornell University, New York, NY; and Robert A. Stern, Boston University, Boston, MA
| |
Collapse
|
42
|
Sabin ND, Cheung YT, Reddick WE, Bhojwani D, Liu W, Glass JO, Brinkman TM, Hwang SN, Srivastava D, Pui CH, Robison LL, Hudson MM, Krull KR. The Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only. AJNR Am J Neuroradiol 2018; 39:1919-1925. [PMID: 30213807 DOI: 10.3174/ajnr.a5791] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Accepted: 07/19/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Survivors of acute lymphoblastic leukemia are at risk for neurocognitive deficits and leukoencephalopathy. We performed a longitudinal assessment of leukoencephalopathy and its associations with long-term brain microstructural white matter integrity and neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a modern chemotherapy-only protocol. MATERIALS AND METHODS One hundred seventy-three survivors of acute lymphoblastic leukemia (49% female), treated on a chemotherapy-only protocol, underwent brain MR imaging during active therapy and repeat imaging and neurocognitive testing at follow-up (median, 13.5 years of age; interquartile range, 10.7-17.6 years; median time since diagnosis, 7.5 years; interquartile range, 6.3-9.1 years). Persistence of leukoencephalopathy was examined in relation to demographic and treatment data and to brain DTI in major fiber tracts and neurocognitive testing at follow-up. RESULTS Leukoencephalopathy was found in 52 of 173 long-term survivors (30.0%) and persisted in 41 of 52 (78.8%) who developed it during therapy. DTI parameters were associated with leukoencephalopathy in multiple brain regions, including the corona radiata (fractional anisotropy, P = .001; mean diffusivity, P < .001), superior longitudinal fasciculi (fractional anisotropy, P = .02; mean diffusivity, P < .001), and superior fronto-occipital fasciculi (fractional anisotropy, P = .006; mean diffusivity, P < .001). Mean diffusivity was associated with neurocognitive impairment including in the genu of the corpus callosum (P = .04), corona radiata (P = .02), and superior fronto-occipital fasciculi (P = .02). CONCLUSIONS Leukoencephalopathy during active therapy and neurocognitive impairment at long-term follow-up are associated with microstructural white matter integrity. DTI may be more sensitive than standard MR imaging for detection of clinically consequential white matter abnormalities in childhood acute lymphoblastic leukemia survivors treated with chemotherapy and in children undergoing treatment.
Collapse
Affiliation(s)
- N D Sabin
- From the Departments of Diagnostic Imaging (N.D.S., W.E.R., J.O.G., S.N.H.)
| | - Y T Cheung
- Epidemiology and Cancer Control (Y.T.C., T.M.B., L.L.R., M.M.H., K.R.K.)
| | - W E Reddick
- From the Departments of Diagnostic Imaging (N.D.S., W.E.R., J.O.G., S.N.H.)
| | - D Bhojwani
- Children's Center for Cancer and Blood Diseases (D.B.), Children's Hospital Los Angeles, Los Angeles, California
| | - W Liu
- Biostatistics (W.L., D.S.)
| | - J O Glass
- From the Departments of Diagnostic Imaging (N.D.S., W.E.R., J.O.G., S.N.H.)
| | - T M Brinkman
- Epidemiology and Cancer Control (Y.T.C., T.M.B., L.L.R., M.M.H., K.R.K.)
- Psychology (T.M.B., K.R.K.)
| | - S N Hwang
- From the Departments of Diagnostic Imaging (N.D.S., W.E.R., J.O.G., S.N.H.)
| | | | - C-H Pui
- Oncology (C.-H.P., M.M.H.), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - L L Robison
- Epidemiology and Cancer Control (Y.T.C., T.M.B., L.L.R., M.M.H., K.R.K.)
| | - M M Hudson
- Epidemiology and Cancer Control (Y.T.C., T.M.B., L.L.R., M.M.H., K.R.K.)
- Oncology (C.-H.P., M.M.H.), St. Jude Children's Research Hospital, Memphis, Tennessee
| | - K R Krull
- Epidemiology and Cancer Control (Y.T.C., T.M.B., L.L.R., M.M.H., K.R.K.)
- Psychology (T.M.B., K.R.K.)
| |
Collapse
|
43
|
Kupeli S, Bicakci K, Sezgin G, Bayram I. Evaluation of late cerebral vascular complications in cranially irradiated pediatric cancer patients with magnetic resonance angiography. TUMORI JOURNAL 2018; 104:381-387. [PMID: 28315509 DOI: 10.5301/tj.5000618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND: We aimed to establish the early diagnosis of cerebral vascular complications by using cerebral magnetic resonance angiography (MRA) in patients who were treated with cranial RT in childhood as part of their cancer treatment. PROCEDURE: Patients who had received cranial RT before the age of 18 and had been in remission for at least 1 year were enrolled in the study. A data form including demographic and clinical characteristics and findings of cerebral MRA was filled in for each patient. RESULTS: Cerebral MRA examination was performed between November 2013 and October 2015 in 53 patients who met the inclusion criteria. Abnormalities were found in 7 patients (13.2%). All patients were asymptomatic at the time of examination. There was a significant difference between patients in the abnormality-positive and abnormality-negative groups related to cranial radiation dose (p = 0.013) and age at the time of examination (p = 0.015) in univariate analysis. In multivariate analysis, cranial radiation dose was found to have an impact on developing cerebral vascular abnormalities (p = 0.045). CONCLUSIONS: Cerebral MRA is a noninvasive method of follow-up for late cerebral vascular complications in surviving pediatric oncology patients who were treated with cranial RT as part of their cancer treatment.
Collapse
Affiliation(s)
- Serhan Kupeli
- 1 Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Çukurova University, Adana - Turkey
| | - Kenan Bicakci
- 2 Department of Radiology, Faculty of Medicine, Çukurova University, Adana - Turkey
| | - Gulay Sezgin
- 1 Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Çukurova University, Adana - Turkey
| | - Ibrahim Bayram
- 1 Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Çukurova University, Adana - Turkey
| |
Collapse
|
44
|
Kesler SR, Ogg R, Reddick WE, Phillips N, Scoggins M, Glass JO, Cheung YT, Pui CH, Robison LL, Hudson MM, Krull KR. Brain Network Connectivity and Executive Function in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. Brain Connect 2018; 8:333-342. [PMID: 29936880 PMCID: PMC6103246 DOI: 10.1089/brain.2017.0574] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Chemotherapeutic agents used to treat acute lymphoblastic leukemia (ALL), the most common cancer affecting young children, have been associated with long-term cognitive impairments that reduce quality of life. Executive dysfunction is one of the most consistently observed deficits and can have substantial and pervasive effects on academic success, occupational achievement, psychosocial function, and psychiatric status. We examined the neural mechanisms of executive dysfunction by measuring structural and functional connectomes in 161 long-term survivors of pediatric ALL, age 8-21 years, who were treated on a single contemporary chemotherapy-only protocol for standard/high- or low-risk disease. Lower global efficiency, a measure of information exchange and network integration, of both structural and functional connectomes was found in survivors with executive dysfunction compared with those without dysfunction (p < 0.046). Patients with standard/high- versus low-risk disease and those who received greater number of intrathecal treatments containing methotrexate had the lowest network efficiencies. Patients with executive dysfunction also showed hyperconnectivity in sensorimotor, visual, and auditory-processing regions (p = 0.037) and poor separation between sensorimotor, executive/attention, salience, and default mode networks (p < 0.0001). Connectome disruption was consistent with a pattern of delayed neurodevelopment that may be associated with reduced resilience, adaptability, and flexibility of the brain network. These findings highlight the need for interventions that will prevent or manage cognitive impairment in survivors of pediatric acute lymphoblastic leukemia.
Collapse
Affiliation(s)
- Shelli R. Kesler
- Department of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Robert Ogg
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Wilburn E. Reddick
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Nicholas Phillips
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Matthew Scoggins
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - John O. Glass
- Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Yin Ting Cheung
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Ching-Hon Pui
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Leslie L. Robison
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Melissa M. Hudson
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Kevin R. Krull
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
- Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee
| |
Collapse
|
45
|
Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer. J Clin Oncol 2018; 36:2181-2189. [PMID: 29874137 DOI: 10.1200/jco.2017.76.4696] [Citation(s) in RCA: 161] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Recent research has demonstrated that survivors of childhood cancer are at risk for a myriad of late effects that affect physical and mental quality of life. We discuss the patterns and prevalence of neurocognitive problems commonly experienced by survivors of CNS tumors and acute lymphoblastic leukemia, the two most commonly researched cancer diagnoses. Research documenting the direct effects of tumor location and treatment type and intensity is presented, and patient characteristics that moderate outcomes (eg, age at diagnosis and sex) are discussed. Potential biologic mechanisms of neurotoxic treatment exposures, such as cranial irradiation and intrathecal and high-dose antimetabolite chemotherapy, are reviewed. Genetic, brain imaging, and neurochemical biomarkers of neurocognitive impairment are discussed. Long-term survivors of childhood cancer are also at risk for physical morbidity (eg, cardiac, pulmonary, endocrine) and problems with health behaviors (eg, sleep); research is reviewed that demonstrates these health problems contribute to neurocognitive impairment in survivors with or without exposure to neurotoxic therapies. We conclude this review with a discussion of literature supporting specific interventions that may be beneficial in the treatment of survivors who already experience neurocognitive impairment, as well as in the prevention of impairment manifestation.
Collapse
Affiliation(s)
- Kevin R Krull
- Kevin R. Krull, St Jude Children's Research Hospital, Memphis, TN; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Lisa S. Kahalley, Baylor College of Medicine; Shelli R. Kesler, University of Texas MD Anderson Cancer Center, Houston, TX; and Ilse Schuitema, Leiden University, Leiden, the Netherlands
| | - Kristina K Hardy
- Kevin R. Krull, St Jude Children's Research Hospital, Memphis, TN; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Lisa S. Kahalley, Baylor College of Medicine; Shelli R. Kesler, University of Texas MD Anderson Cancer Center, Houston, TX; and Ilse Schuitema, Leiden University, Leiden, the Netherlands
| | - Lisa S Kahalley
- Kevin R. Krull, St Jude Children's Research Hospital, Memphis, TN; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Lisa S. Kahalley, Baylor College of Medicine; Shelli R. Kesler, University of Texas MD Anderson Cancer Center, Houston, TX; and Ilse Schuitema, Leiden University, Leiden, the Netherlands
| | - Ilse Schuitema
- Kevin R. Krull, St Jude Children's Research Hospital, Memphis, TN; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Lisa S. Kahalley, Baylor College of Medicine; Shelli R. Kesler, University of Texas MD Anderson Cancer Center, Houston, TX; and Ilse Schuitema, Leiden University, Leiden, the Netherlands
| | - Shelli R Kesler
- Kevin R. Krull, St Jude Children's Research Hospital, Memphis, TN; Kristina K. Hardy, Children's National Medical Center, Washington, DC; Lisa S. Kahalley, Baylor College of Medicine; Shelli R. Kesler, University of Texas MD Anderson Cancer Center, Houston, TX; and Ilse Schuitema, Leiden University, Leiden, the Netherlands
| |
Collapse
|
46
|
Marusak HA, Iadipaolo AS, Harper FW, Elrahal F, Taub JW, Goldberg E, Rabinak CA. Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes. Neuropsychol Rev 2018; 28:123-175. [PMID: 29270773 PMCID: PMC6639713 DOI: 10.1007/s11065-017-9365-1] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 11/08/2017] [Indexed: 01/29/2023]
Abstract
Today, children are surviving pediatric cancer at unprecedented rates, making it one of modern medicine's true success stories. However, we are increasingly becoming aware of several deleterious effects of cancer and the subsequent "cure" that extend beyond physical sequelae. Indeed, survivors of childhood cancer commonly report cognitive, emotional, and psychological difficulties, including attentional difficulties, anxiety, and posttraumatic stress symptoms (PTSS). Cognitive late- and long-term effects have been largely attributed to neurotoxic effects of cancer treatments (e.g., chemotherapy, cranial irradiation, surgery) on brain development. The role of childhood adversity in pediatric cancer - namely, the presence of a life-threatening disease and endurance of invasive medical procedures - has been largely ignored in the existing neuroscientific literature, despite compelling research by our group and others showing that exposure to more commonly studied adverse childhood experiences (i.e., domestic and community violence, physical, sexual, and emotional abuse) strongly imprints on neural development. While these adverse childhood experiences are different in many ways from the experience of childhood cancer (e.g., context, nature, source), they do share a common element of exposure to threat (i.e., threat to life or physical integrity). Therefore, we argue that the double hit of early threat and cancer treatments likely alters neural development, and ultimately, cognitive, behavioral, and emotional outcomes. In this paper, we (1) review the existing neuroimaging research on child, adolescent, and adult survivors of childhood cancer, (2) summarize gaps in our current understanding, (3) propose a novel neurobiological framework that characterizes childhood cancer as a type of childhood adversity, particularly a form of early threat, focusing on development of the hippocampus and the salience and emotion network (SEN), and (4) outline future directions for research.
Collapse
Affiliation(s)
- Hilary A Marusak
- Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Suite 2190, Detroit, MI, 48202, USA.
| | - Allesandra S Iadipaolo
- Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Suite 2190, Detroit, MI, 48202, USA
| | - Felicity W Harper
- Population Studies and Disparities Research Program, Karmanos Cancer Institute, Detroit, MI, USA
- Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA
| | - Farrah Elrahal
- Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Suite 2190, Detroit, MI, 48202, USA
| | - Jeffrey W Taub
- Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI, USA
- Children's Hospital of Michigan, Detroit, MI, USA
| | - Elimelech Goldberg
- Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI, USA
- Kids Kicking Cancer, Southfield, MI, USA
| | - Christine A Rabinak
- Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Suite 2190, Detroit, MI, 48202, USA
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
- Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, USA
| |
Collapse
|
47
|
Alias H, Lau SCD, Schuitema I, de Sonneville LMJ. Neuropsychological Consequences for Survivors of Childhood Brain Tumor in Malaysia. Front Psychol 2018; 9:703. [PMID: 29896137 PMCID: PMC5986920 DOI: 10.3389/fpsyg.2018.00703] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 04/23/2018] [Indexed: 01/06/2023] Open
Abstract
Objective: This study aimed to evaluate neuropsychological consequences in survivors of childhood brain tumor. Method: A case-control study was conducted over a period of 4 months in a tertiary referral center in Kuala Lumpur, Malaysia. Fourteen survivors of childhood brain tumor aged 7–18 years, who were off-treatment for at least 1 year and were in remission, and 31 unrelated healthy controls were recruited. The median age at diagnosis was 8.20 years (range: 0.92–12.96 years). The diagnoses of brain tumors were medulloblastoma, germ cell tumor, pineocytoma, pilocystic astrocytoma, suprasellar germinoma, and ependymoma. Eleven survivors received central nervous system irradiation. Seven tasks were selected from the Amsterdam Neuropsychological Tasks program to evaluate alertness (processing speed), and major aspects of executive functioning, such as working memory capacity, inhibition, cognitive flexibility, and sustained attention. Speed, stability and accuracy of responses were the main outcome measures. Results: Survivors of childhood brain tumor showed statistically significant poorer performance on all tasks compared to healthy controls. Both processing speed and accuracy were impaired in the survivors, in particular under more complex task conditions. The survivors demonstrated deficits in alertness, sustained attention, working memory capacity, executive visuomotor control, and cognitive flexibility. Longer duration off treatment appeared to be correlated with poorer alertness, memory capacity, and inhibition. Conclusion: Survivors of childhood brain tumor in our center showed impaired neuropsychological functioning. Development of less toxic treatment protocols is important to prevent late effects of cognitive deficits in survivors of childhood brain tumor.
Collapse
Affiliation(s)
- Hamidah Alias
- Department of Pediatrics, UKM Medical Center, Faculty of Medicine, The National University of Malaysia, Kuala Lumpur, Malaysia
| | - Sie Chong D Lau
- Department of Pediatrics, UKM Medical Center, Faculty of Medicine, The National University of Malaysia, Kuala Lumpur, Malaysia
| | - Ilse Schuitema
- Department of Clinical Child and Adolescent Studies, Faculty of Social Sciences, Leiden University, Leiden, Netherlands
| | - Leo M J de Sonneville
- Department of Clinical Child and Adolescent Studies, Faculty of Social Sciences, Leiden University, Leiden, Netherlands
| |
Collapse
|
48
|
Darling SJ, De Luca C, Anderson V, McCarthy M, Hearps S, Seal ML. White Matter Microstructure and Information Processing at the Completion of Chemotherapy-Only Treatment for Pediatric Acute Lymphoblastic Leukemia. Dev Neuropsychol 2018; 43:385-402. [DOI: 10.1080/87565641.2018.1473401] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Affiliation(s)
- Simone J Darling
- Clinical Sciences, Murdoch Children’s Research Institute, Parkville, Australia
- Department of Paediatrics, The University of Melbourne, Parkville, Australia
| | - Cinzia De Luca
- Clinical Sciences, Murdoch Children’s Research Institute, Parkville, Australia
- Children’s Cancer Centre, Royal Children’s Hospital, Parkville, Australia
| | - Vicki Anderson
- Clinical Sciences, Murdoch Children’s Research Institute, Parkville, Australia
- Department of Paediatrics, The University of Melbourne, Parkville, Australia
- Psychology Department, The Royal Children’s Hospital, Parkville, Australia
| | - Maria McCarthy
- Clinical Sciences, Murdoch Children’s Research Institute, Parkville, Australia
- Children’s Cancer Centre, Royal Children’s Hospital, Parkville, Australia
| | - Stephen Hearps
- Clinical Sciences, Murdoch Children’s Research Institute, Parkville, Australia
| | - Marc L Seal
- Clinical Sciences, Murdoch Children’s Research Institute, Parkville, Australia
- Department of Paediatrics, The University of Melbourne, Parkville, Australia
| |
Collapse
|
49
|
Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci Biobehav Rev 2018; 92:304-317. [PMID: 29791867 DOI: 10.1016/j.neubiorev.2018.05.019] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 05/08/2018] [Accepted: 05/14/2018] [Indexed: 12/26/2022]
Abstract
In addition to the burden of a life-threatening diagnosis, cancer patients are struggling with adverse side-effects from cancer treatment. Chemotherapy has been linked to an array of cognitive impairments and alterations in brain structure and function ("chemobrain"). In this review, we summarized the existing evidence that evaluate the changes in cognitive functioning and brain with chemotherapy, as assessed using structural and functional MRI-based techniques in a longitudinal design. This review followed the latest PRISMA guidelines using Embase, Medline, PsychINFO, Scopus, and Web of Science databases with date restrictions from 2012 to 2017. Fourteen research articles met the key inclusion criteria: (i) the studies involved adult cancer patients (mean age ≥ 18); (ii) the use of chemotherapy in the treatment of cancer; (iii) pre-post assessment of behavioral and brain-based outcomes; and (iv) abstracts written in English. Effect sizes of subjective and objective cognitive impairments from the reviewed studies were estimated using Cohen's d or z-scores. We calculated percentage of mean change or effect sizes for main neuroimaging findings when data were available. Strength of the correlations between brain alterations and cognitive changes was obtained using squared correlation coefficients. Small to medium effect sizes were shown? on individual tests of attention, processing speed, verbal memory, and executive control; and medium effect sizes on self-report questionnaires. Neuroimaging data showed reduced grey matter density in cancer patients in frontal, parietal, and temporal regions. Changes in brain function (brain activation and cerebral blood flow) were observed with cancer across functional networks involving (pre)frontal, parietal, occipital, temporal, and cerebellar regions. Data from diffusion-weighted MRI suggested reduced white matter integrity involving the superior longitudinal fasciculus, corpus callosum, forceps major, and corona radiate, and altered structural connectivity across the whole brain network. Finally, we observed moderate-to-strong correlations between worsening cognitive function and morphological changes in frontal brain regions. While MRI is a powerful tool for detection of longitudinal brain changes in the 'chemobrain', the underlying biological mechanisms are still unclear. Continued work in this field will hopefully detect MRI metrics to be used as biomarkers to help guide cognitive treatment at the individual cancer patient level.
Collapse
|
50
|
Sleurs C, Lemiere J, Christiaens D, Billiet T, Peeters R, Sunaert S, Uyttebroeck A, Deprez S. Advanced MR diffusion imaging and chemotherapy-related changes in cerebral white matter microstructure of survivors of childhood bone and soft tissue sarcoma? Hum Brain Mapp 2018; 39:3375-3387. [PMID: 29675944 DOI: 10.1002/hbm.24082] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 04/03/2018] [Accepted: 04/04/2018] [Indexed: 12/13/2022] Open
Abstract
With the increase of survival rates of pediatric cancer patients, the number of children facing potential cognitive sequelae has grown. Previous adult studies suggest that white matter (WM) microstructural changes may contribute to cognitive impairment. This study aims to investigate WM microstructure in childhood bone and soft tissue sarcoma. Differences in (micro-)structure can be investigated using diffusion MRI (dMRI). The typically used diffusion tensor model (DTI) assumes Gaussian diffusion, and lacks information about fiber populations. In this study, we compare WM structure of childhood bone and soft tissue sarcoma survivors (n = 34) and matched controls (n = 34), combining typical and advanced voxel-based models (DTI and NODDI model, respectively), as well as recently developed fixel-based models (for estimations of intra-voxel differences, apparent fiber density [AFD] and fiber cross-section [FC]). Parameters with significant findings were compared between treatments, and correlated with subscales of the WAIS-IV intelligence test, age at diagnosis, age at assessment and time since diagnosis. We encountered extensive regions showing lower fractional anisotropy, overlapping with both significant NODDI parameters and fixel-based parameters. In contrast to these diffuse differences, the fixel-based measure of AFD was reduced in the cingulum and corpus callosum only. Furthermore, AFD of the corpus callosum was significantly predicted by chemotherapy treatment and correlated positively with time since diagnosis, visual puzzles and similarities task scores. This study suggests altered WM structure of childhood bone and soft tissue sarcoma survivors. We conclude global chemotherapy-related changes, with particular vulnerability of centrally located WM bundles. Finally, such differences could potentially recover after treatment.
Collapse
Affiliation(s)
- Charlotte Sleurs
- Department of Pediatrics, University Hospitals Leuven, UZ Leuven, Belgium.,Department of Radiology, University Hospitals Leuven, UZ Leuven, Belgium.,Department of Oncology, UZ Leuven, Belgium
| | - Jurgen Lemiere
- Department of Pediatrics, University Hospitals Leuven, UZ Leuven, Belgium
| | - Daan Christiaens
- Centre for the Developing Brain, King's College London, London, United Kingdom
| | - Thibo Billiet
- Imaging Biomarker Experts, Icometrix, Leuven, Belgium
| | - Ronald Peeters
- Department of Radiology, University Hospitals Leuven, UZ Leuven, Belgium
| | - Stefan Sunaert
- Department of Radiology, University Hospitals Leuven, UZ Leuven, Belgium.,Department of Imaging and Pathology, UZ Leuven, Belgium
| | - Anne Uyttebroeck
- Department of Pediatrics, University Hospitals Leuven, UZ Leuven, Belgium.,Department of Oncology, UZ Leuven, Belgium
| | - Sabine Deprez
- Department of Radiology, University Hospitals Leuven, UZ Leuven, Belgium.,Department of Imaging and Pathology, UZ Leuven, Belgium
| |
Collapse
|